JP2019532981A - 融合アザヘテロ環状化合物、及びampa受容体調節因子としてのそれらの使用 - Google Patents
融合アザヘテロ環状化合物、及びampa受容体調節因子としてのそれらの使用 Download PDFInfo
- Publication number
- JP2019532981A JP2019532981A JP2019522818A JP2019522818A JP2019532981A JP 2019532981 A JP2019532981 A JP 2019532981A JP 2019522818 A JP2019522818 A JP 2019522818A JP 2019522818 A JP2019522818 A JP 2019522818A JP 2019532981 A JP2019532981 A JP 2019532981A
- Authority
- JP
- Japan
- Prior art keywords
- trifluoromethyl
- methyl
- indazol
- pyridine
- triazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 499
- 102000003678 AMPA Receptors Human genes 0.000 title claims description 77
- 108090000078 AMPA Receptors Proteins 0.000 title claims description 77
- 230000004927 fusion Effects 0.000 title description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 60
- 239000012453 solvate Substances 0.000 claims abstract description 38
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 65
- 125000000217 alkyl group Chemical group 0.000 claims description 63
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 60
- -1 2- (difluoromethyl) -7- (trifluoromethyl)-[1,2,4] triazolo [1,5-a] pyridin-8-yl Chemical group 0.000 claims description 41
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 37
- 125000002393 azetidinyl group Chemical group 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 28
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 230000001404 mediated effect Effects 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 206010015037 epilepsy Diseases 0.000 claims description 14
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 201000000980 schizophrenia Diseases 0.000 claims description 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 210000004556 brain Anatomy 0.000 claims description 9
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 208000010877 cognitive disease Diseases 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 5
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 5
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 5
- MHLASTDYGRVTDH-UHFFFAOYSA-N 6-[7-(4-fluorophenyl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-3H-1,3-benzothiazol-2-one Chemical compound FC1=CC=C(C=C1)C1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C1=CC2=C(NC(S2)=O)C=C1 MHLASTDYGRVTDH-UHFFFAOYSA-N 0.000 claims description 4
- RJOMMGYSOKSCQH-UHFFFAOYSA-N 7-chloro-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C RJOMMGYSOKSCQH-UHFFFAOYSA-N 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 208000016192 Demyelinating disease Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- LEEYUYGHXPEDSB-UHFFFAOYSA-N 2-(difluoromethyl)-8-(7-methyl-1H-indazol-5-yl)-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound FC(C=1N=C2N(C=NC(=C2C=2C=C3C=NNC3=C(C=2)C)C(F)(F)F)C=1)F LEEYUYGHXPEDSB-UHFFFAOYSA-N 0.000 claims description 3
- QSCIZKKPKOIJLE-UHFFFAOYSA-N 2-cyclobutyl-7-(4-fluorophenyl)-8-(7-methyl-1H-indazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1(CCC1)C1=NN2C(C(=C(C=C2)C2=CC=C(C=C2)F)C=2C=C3C=NNC3=C(C=2)C)=N1 QSCIZKKPKOIJLE-UHFFFAOYSA-N 0.000 claims description 3
- OYAQXKCMCBNBFS-UHFFFAOYSA-N 5-[2,7-bis(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-7-methyl-1,3-dihydroindol-2-one Chemical compound FC(C1=NN2C(C(=C(C=C2)C(F)(F)F)C=2C=C3CC(NC3=C(C=2)C)=O)=N1)(F)F OYAQXKCMCBNBFS-UHFFFAOYSA-N 0.000 claims description 3
- WZMMCQQKCBQNDM-UHFFFAOYSA-N 6-[2,7-bis(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-3H-1,3-benzothiazol-2-one Chemical compound FC(C1=NN2C(C(=C(C=C2)C(F)(F)F)C2=CC3=C(NC(S3)=O)C=C2)=N1)(F)F WZMMCQQKCBQNDM-UHFFFAOYSA-N 0.000 claims description 3
- ZETXBXSZFCWEIU-UHFFFAOYSA-N 7-(3-fluoroazetidin-1-yl)-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound FC1CN(C1)C1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C ZETXBXSZFCWEIU-UHFFFAOYSA-N 0.000 claims description 3
- DOZPHMBSHRGCPJ-UHFFFAOYSA-N 7-(4-fluorophenyl)-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound FC1=CC=C(C=C1)C1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C DOZPHMBSHRGCPJ-UHFFFAOYSA-N 0.000 claims description 3
- BDELKWZFIDKHBS-UHFFFAOYSA-N 7-cyclopentyl-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1(CCCC1)C1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C BDELKWZFIDKHBS-UHFFFAOYSA-N 0.000 claims description 3
- BTYHNCVKMZGINW-UHFFFAOYSA-N 8-(1H-indazol-5-yl)-2,7-bis(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound FC(C=1N=C2N(C=CC(=C2C=2C=C3C=NNC3=CC=2)C(F)(F)F)C=1)(F)F BTYHNCVKMZGINW-UHFFFAOYSA-N 0.000 claims description 3
- GGKONIYAUIXOKL-UHFFFAOYSA-N 8-(2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-5-yl)-7-(4-fluorophenyl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound Fc1ccc(cc1)-c1ccn2nc(nc2c1C1CCC2NNCC2C1)C(F)(F)F GGKONIYAUIXOKL-UHFFFAOYSA-N 0.000 claims description 3
- NVWZZVUPFYUJPP-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-cyclopropyl-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C1CC1 NVWZZVUPFYUJPP-UHFFFAOYSA-N 0.000 claims description 3
- JBJVUUZVRBFXJA-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-propan-2-yl-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C(C)C JBJVUUZVRBFXJA-UHFFFAOYSA-N 0.000 claims description 3
- DQWRORKRBWZKME-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-7-(difluoromethyl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)F)N=C(N=2)C(F)(F)F DQWRORKRBWZKME-UHFFFAOYSA-N 0.000 claims description 3
- CJEQVSUBYGYUQT-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-7-cyclopropyl-5-methyl-2-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound CC1=NC(C2CC2)=C(C2=NC(=CN12)C(F)(F)F)C1=CC(Cl)=C2NN=CC2=C1 CJEQVSUBYGYUQT-UHFFFAOYSA-N 0.000 claims description 3
- FFPHRXURPVVSGG-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-7-propan-2-yl-2-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1C(C)C)C=C(N=2)C(F)(F)F FFPHRXURPVVSGG-UHFFFAOYSA-N 0.000 claims description 3
- WKEMSMWQAOLEPU-UHFFFAOYSA-N 8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine-7-carbonitrile Chemical compound CC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C#N)N=C(N=2)C(F)(F)F WKEMSMWQAOLEPU-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 206010016952 Food poisoning Diseases 0.000 claims description 3
- 208000019331 Foodborne disease Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 206010065681 HIV peripheral neuropathy Diseases 0.000 claims description 3
- 206010019196 Head injury Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 3
- 206010028570 Myelopathy Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000011235 central nervous system lupus Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 3
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000023105 myelination Effects 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 3
- 208000018198 spasticity Diseases 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- XZPCBPSVTOHPGN-UHFFFAOYSA-N 2-(difluoromethyl)-7-(4-fluorophenyl)-8-(7-methyl-1H-indazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound FC(C1=NN2C(C(=C(C=C2)C2=CC=C(C=C2)F)C=2C=C3C=NNC3=C(C=2)C)=N1)F XZPCBPSVTOHPGN-UHFFFAOYSA-N 0.000 claims description 2
- FSWWDNJXDOAKBG-UHFFFAOYSA-N 2-(difluoromethyl)-8-(7-methyl-1H-indazol-5-yl)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound CC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C(F)F FSWWDNJXDOAKBG-UHFFFAOYSA-N 0.000 claims description 2
- LPEQXVAANQPODW-UHFFFAOYSA-N 2-cyclopentyl-7-(4-fluorophenyl)-8-(7-methyl-1H-indazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1(CCCC1)C1=NN2C(C(=C(C=C2)C2=CC=C(C=C2)F)C=2C=C3C=NNC3=C(C=2)C)=N1 LPEQXVAANQPODW-UHFFFAOYSA-N 0.000 claims description 2
- CWEYUTZTXLDDJA-UHFFFAOYSA-N 2-cyclopropyl-7-(4-fluorophenyl)-8-(7-methyl-1H-indazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1(CC1)C1=NN2C(C(=C(C=C2)C2=CC=C(C=C2)F)C=2C=C3C=NNC3=C(C=2)C)=N1 CWEYUTZTXLDDJA-UHFFFAOYSA-N 0.000 claims description 2
- ZAYKKCRUFNJAEN-UHFFFAOYSA-N 2-cyclopropyl-7-methyl-8-(7-methyl-1H-indazol-5-yl)imidazo[1,2-a]pyridine Chemical compound C1(CC1)C=1N=C2N(C=CC(=C2C=2C=C3C=NNC3=C(C=2)C)C)C=1 ZAYKKCRUFNJAEN-UHFFFAOYSA-N 0.000 claims description 2
- MEIUEUQZTNMVBI-UHFFFAOYSA-N 2-cyclopropyl-8-(7-methyl-1H-indazol-5-yl)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1(CC1)C1=NN2C(C(=C(C=C2)C(F)(F)F)C=2C=C3C=NNC3=C(C=2)C)=N1 MEIUEUQZTNMVBI-UHFFFAOYSA-N 0.000 claims description 2
- JDOFYDBGQSJBAV-UHFFFAOYSA-N 2-cyclopropyl-8-(7-methyl-1H-indazol-5-yl)-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound C1(CC1)C=1N=C2N(C=CC(=C2C=2C=C3C=NNC3=C(C=2)C)C(F)(F)F)C=1 JDOFYDBGQSJBAV-UHFFFAOYSA-N 0.000 claims description 2
- BIONNSBESIPGQI-UHFFFAOYSA-N 2-cyclopropyl-8-(7-methyl-1H-indazol-5-yl)-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound C1(CC1)C=1N=C2N(C=NC(=C2C=2C=C3C=NNC3=C(C=2)C)C(F)(F)F)C=1 BIONNSBESIPGQI-UHFFFAOYSA-N 0.000 claims description 2
- JUHJELMFIVVMNS-UHFFFAOYSA-N 2-ethyl-8-(7-methyl-1H-indazol-5-yl)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C(C)C1=NN2C(C(=C(C=C2)C(F)(F)F)C=2C=C3C=NNC3=C(C=2)C)=N1 JUHJELMFIVVMNS-UHFFFAOYSA-N 0.000 claims description 2
- KZDAZPDVGOESOJ-UHFFFAOYSA-N 2-ethyl-8-(7-methyl-1H-indazol-5-yl)-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound C(C)C=1N=C2N(C=CC(=C2C=2C=C3C=NNC3=C(C=2)C)C(F)(F)F)C=1 KZDAZPDVGOESOJ-UHFFFAOYSA-N 0.000 claims description 2
- MXFLJLJDTSIAMF-UHFFFAOYSA-N 2-ethyl-8-(7-methyl-1H-indazol-5-yl)-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound C(C)C=1N=C2N(C=NC(=C2C=2C=C3C=NNC3=C(C=2)C)C(F)(F)F)C=1 MXFLJLJDTSIAMF-UHFFFAOYSA-N 0.000 claims description 2
- FELYLJINEBSAMA-UHFFFAOYSA-N 2-methyl-8-(7-methyl-1H-indazol-5-yl)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound CC1=NN2C(C(=C(C=C2)C(F)(F)F)C=2C=C3C=NNC3=C(C=2)C)=N1 FELYLJINEBSAMA-UHFFFAOYSA-N 0.000 claims description 2
- SUPXDFKXJDYRGO-UHFFFAOYSA-N 2-methyl-8-(7-methyl-1H-indazol-5-yl)-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound CC=1N=C2N(C=CC(=C2C=2C=C3C=NNC3=C(C=2)C)C(F)(F)F)C=1 SUPXDFKXJDYRGO-UHFFFAOYSA-N 0.000 claims description 2
- SPJOSQHVPJAVKI-UHFFFAOYSA-N 2-tert-butyl-7-methyl-8-(7-methyl-1H-indazol-5-yl)imidazo[1,2-a]pyridine Chemical compound C(C)(C)(C)C=1N=C2N(C=CC(=C2C=2C=C3C=NNC3=C(C=2)C)C)C=1 SPJOSQHVPJAVKI-UHFFFAOYSA-N 0.000 claims description 2
- BWIUNRVEFKKBNU-UHFFFAOYSA-N 3-chloro-8-(7-chloro-1H-indazol-5-yl)-2-cyclopropyl-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound ClC1=C(N=C2N1C=NC(=C2C=1C=C2C=NNC2=C(C=1)Cl)C(F)(F)F)C1CC1 BWIUNRVEFKKBNU-UHFFFAOYSA-N 0.000 claims description 2
- MCGJOSPBFNTIJO-UHFFFAOYSA-N 5-(2-tert-butyl-7-methylimidazo[1,2-a]pyridin-8-yl)-7-methyl-1,3-dihydroindol-2-one Chemical compound C(C)(C)(C)C=1N=C2N(C=CC(=C2C=2C=C3CC(NC3=C(C=2)C)=O)C)C=1 MCGJOSPBFNTIJO-UHFFFAOYSA-N 0.000 claims description 2
- WADNTVQMSDGRNQ-UHFFFAOYSA-N 5-[2,7-bis(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-7-chloro-1,3-dihydroindol-2-one Chemical compound FC(C1=NN2C(C(=C(C=C2)C(F)(F)F)C=2C=C3CC(NC3=C(C=2)Cl)=O)=N1)(F)F WADNTVQMSDGRNQ-UHFFFAOYSA-N 0.000 claims description 2
- OJUNYOMQROIORI-UHFFFAOYSA-N 5-[2,7-bis(trifluoromethyl)imidazo[1,2-a]pyridin-8-yl]-7-chloro-1,3-dihydroindol-2-one Chemical compound FC(C=1N=C2N(C=CC(=C2C=2C=C3CC(NC3=C(C=2)Cl)=O)C(F)(F)F)C=1)(F)F OJUNYOMQROIORI-UHFFFAOYSA-N 0.000 claims description 2
- HDWDXSUOBZTWFG-UHFFFAOYSA-N 5-[2,7-bis(trifluoromethyl)imidazo[1,2-a]pyridin-8-yl]-7-methyl-1,3-dihydroindol-2-one Chemical compound FC(C=1N=C2N(C=CC(=C2C=2C=C3CC(NC3=C(C=2)C)=O)C(F)(F)F)C=1)(F)F HDWDXSUOBZTWFG-UHFFFAOYSA-N 0.000 claims description 2
- DHRXCMUCNSVFOL-UHFFFAOYSA-N 5-[2-(difluoromethyl)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-7-methyl-1,3-dihydroindol-2-one Chemical compound CC=1C=C(C=C2CC(NC=12)=O)C=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C(F)F DHRXCMUCNSVFOL-UHFFFAOYSA-N 0.000 claims description 2
- ZXETTYZYOYRSDB-UHFFFAOYSA-N 5-[2-cyclopropyl-7-(trifluoromethyl)imidazo[1,2-c]pyrimidin-8-yl]-7-fluoro-1,3-dihydroindol-2-one Chemical compound C1(CC1)C=1N=C2N(C=NC(=C2C=2C=C3CC(NC3=C(C=2)F)=O)C(F)(F)F)C=1 ZXETTYZYOYRSDB-UHFFFAOYSA-N 0.000 claims description 2
- XHNKPBLDWIVGDK-UHFFFAOYSA-N 5-[2-ethyl-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-7-methyl-1,3-dihydroindol-2-one Chemical compound C(C)C1=NN2C(C(=C(C=C2)C(F)(F)F)C=2C=C3CC(NC3=C(C=2)C)=O)=N1 XHNKPBLDWIVGDK-UHFFFAOYSA-N 0.000 claims description 2
- ZURMWIHNPMLDNU-UHFFFAOYSA-N 5-[7-(difluoromethyl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-7-methyl-1,3-dihydroindol-2-one Chemical compound CC=1C=C(C=C2CC(NC=12)=O)C=1C=2N(C=CC=1C(F)F)N=C(N=2)C(F)(F)F ZURMWIHNPMLDNU-UHFFFAOYSA-N 0.000 claims description 2
- MXSWBEVSEQJDJN-UHFFFAOYSA-N 5-[7-methoxy-2-(trifluoromethyl)imidazo[1,2-a]pyridin-8-yl]-7-methyl-1,3-dihydroindol-2-one Chemical compound COC1=C(C=2N(C=C1)C=C(N=2)C(F)(F)F)C=1C=C2CC(NC2=C(C=1)C)=O MXSWBEVSEQJDJN-UHFFFAOYSA-N 0.000 claims description 2
- VQGSZLLPHOJBDD-UHFFFAOYSA-N 7-(4-fluorophenyl)-2-(methoxymethyl)-8-(7-methyl-1H-indazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound FC1=CC=C(C=C1)C1=C(C=2N(C=C1)N=C(N=2)COC)C=1C=C2C=NNC2=C(C=1)C VQGSZLLPHOJBDD-UHFFFAOYSA-N 0.000 claims description 2
- BUSMMEKEWJWVMS-UHFFFAOYSA-N 7-(azetidin-1-yl)-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound N1(CCC1)C1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C BUSMMEKEWJWVMS-UHFFFAOYSA-N 0.000 claims description 2
- NWBKGKGTTGQLET-UHFFFAOYSA-N 7-(difluoromethyl)-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound CC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)F)N=C(N=2)C(F)(F)F NWBKGKGTTGQLET-UHFFFAOYSA-N 0.000 claims description 2
- KENOPWYIBOIRJE-UHFFFAOYSA-N 7-chloro-5-[2-cyclopropyl-7-(trifluoromethyl)imidazo[1,2-c]pyrimidin-8-yl]-1,3-dihydroindol-2-one Chemical compound ClC=1C=C(C=C2CC(NC=12)=O)C=1C=2N(C=NC=1C(F)(F)F)C=C(N=2)C1CC1 KENOPWYIBOIRJE-UHFFFAOYSA-N 0.000 claims description 2
- XVKHARRKJAULOT-UHFFFAOYSA-N 7-chloro-5-[7-(difluoromethyl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-1,3-dihydroindol-2-one Chemical compound ClC=1C=C(C=C2CC(NC=12)=O)C=1C=2N(C=CC=1C(F)F)N=C(N=2)C(F)(F)F XVKHARRKJAULOT-UHFFFAOYSA-N 0.000 claims description 2
- GYKVBSCJPHIEQL-UHFFFAOYSA-N 7-chloro-8-(7-chloro-1H-indazol-5-yl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)Cl GYKVBSCJPHIEQL-UHFFFAOYSA-N 0.000 claims description 2
- GMRUVNBZIBVCOP-UHFFFAOYSA-N 7-chloro-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound ClC1=C(C=2N(C=C1)C=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C GMRUVNBZIBVCOP-UHFFFAOYSA-N 0.000 claims description 2
- SCDFCFCMJOYQDX-UHFFFAOYSA-N 7-cyclopropyl-2-(difluoromethyl)-5-methyl-8-[7-(trifluoromethyl)-1H-indazol-5-yl]imidazo[1,2-c]pyrimidine Chemical compound C1(CC1)C1=C(C=2N(C(=N1)C)C=C(N=2)C(F)F)C=1C=C2C=NNC2=C(C=1)C(F)(F)F SCDFCFCMJOYQDX-UHFFFAOYSA-N 0.000 claims description 2
- AJBZJWLOCCAINX-UHFFFAOYSA-N 7-ethyl-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C(C)C1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C AJBZJWLOCCAINX-UHFFFAOYSA-N 0.000 claims description 2
- XFBKZSQPDQLSDN-UHFFFAOYSA-N 7-ethyl-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound C(C)C1=C(C=2N(C=N1)C=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C XFBKZSQPDQLSDN-UHFFFAOYSA-N 0.000 claims description 2
- DNCGWEXWXYZBHO-UHFFFAOYSA-N 7-fluoro-5-[7-methyl-2-(trifluoromethyl)imidazo[1,2-a]pyridin-8-yl]-1,3-dihydroindol-2-one Chemical compound FC=1C=C(C=C2CC(NC=12)=O)C=1C=2N(C=CC=1C)C=C(N=2)C(F)(F)F DNCGWEXWXYZBHO-UHFFFAOYSA-N 0.000 claims description 2
- GNQAHZTWJVNGIO-UHFFFAOYSA-N 7-methoxy-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound COC1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C GNQAHZTWJVNGIO-UHFFFAOYSA-N 0.000 claims description 2
- WZNJIEMBDWKKOF-UHFFFAOYSA-N 7-methoxy-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound COC1=C(C=2N(C=C1)C=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C WZNJIEMBDWKKOF-UHFFFAOYSA-N 0.000 claims description 2
- KAEBBPZGBCBWCV-UHFFFAOYSA-N 7-methyl-5-(7-methyl-2-phenylimidazo[1,2-a]pyridin-8-yl)-1,3-dihydroindol-2-one Chemical compound CC=1C=C(C=C2CC(NC=12)=O)C=1C=2N(C=CC=1C)C=C(N=2)C1=CC=CC=C1 KAEBBPZGBCBWCV-UHFFFAOYSA-N 0.000 claims description 2
- YBSZRGHMUDDSEM-UHFFFAOYSA-N 7-methyl-5-[2-propan-2-yl-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-1,3-dihydroindol-2-one Chemical compound C(C)(C)C1=NN2C(C(=C(C=C2)C(F)(F)F)C=2C=C3CC(NC3=C(C=2)C)=O)=N1 YBSZRGHMUDDSEM-UHFFFAOYSA-N 0.000 claims description 2
- DEFTVOKPYXCOPW-UHFFFAOYSA-N 7-methyl-5-[7-methyl-2-(trifluoromethyl)imidazo[1,2-a]pyridin-8-yl]-1,3-dihydroindol-2-one Chemical compound CC=1C=C(C=C2CC(NC=12)=O)C=1C=2N(C=CC=1C)C=C(N=2)C(F)(F)F DEFTVOKPYXCOPW-UHFFFAOYSA-N 0.000 claims description 2
- GAEMBEGWSKKZHQ-UHFFFAOYSA-N 7-methyl-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound CC1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C GAEMBEGWSKKZHQ-UHFFFAOYSA-N 0.000 claims description 2
- YYTFRKLGZLOESX-UHFFFAOYSA-N 7-methyl-8-(7-methyl-1H-indazol-5-yl)-2-phenylimidazo[1,2-a]pyridine Chemical compound CC1=C(C=2N(C=C1)C=C(N=2)C1=CC=CC=C1)C=1C=C2C=NNC2=C(C=1)C YYTFRKLGZLOESX-UHFFFAOYSA-N 0.000 claims description 2
- ANISZQCWYOQOME-UHFFFAOYSA-N 7-methyl-8-(7-methyl-1H-indazol-5-yl)-2-propan-2-yl-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C(C)(C)C1=NN2C(C(=C(C=C2)C)C=2C=C3C=NNC3=C(C=2)C)=N1 ANISZQCWYOQOME-UHFFFAOYSA-N 0.000 claims description 2
- LJDORQILANXCJF-UHFFFAOYSA-N 8-(1H-indazol-5-yl)-7-methyl-2-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound N1N=CC2=CC(=CC=C12)C=1C=2N(C=CC=1C)C=C(N=2)C(F)(F)F LJDORQILANXCJF-UHFFFAOYSA-N 0.000 claims description 2
- TULQGHLAFSOUEN-UHFFFAOYSA-N 8-(3-fluoro-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-5-yl)-7-(4-fluorophenyl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound FC1NNC2CCC(CC12)c1c(ccn2nc(nc12)C(F)(F)F)-c1ccc(F)cc1 TULQGHLAFSOUEN-UHFFFAOYSA-N 0.000 claims description 2
- QOJKLLQYDWXAJB-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2,7-bis(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C(F)(F)F QOJKLLQYDWXAJB-UHFFFAOYSA-N 0.000 claims description 2
- SSJJQPAUORKMHJ-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2,7-bis(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound FC(C=1N=C2N(C=CC(=C2C=2C=C3C=NNC3=C(C=2)Cl)C(F)(F)F)C=1)(F)F SSJJQPAUORKMHJ-UHFFFAOYSA-N 0.000 claims description 2
- KWDVIOOOKSBXLA-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2,7-bis(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1C(F)(F)F)C=C(N=2)C(F)(F)F KWDVIOOOKSBXLA-UHFFFAOYSA-N 0.000 claims description 2
- KMPBDXASOBUDTP-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-(difluoromethyl)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C(F)F KMPBDXASOBUDTP-UHFFFAOYSA-N 0.000 claims description 2
- MDZCIAZOUBWBQP-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-(difluoromethyl)-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1C(F)(F)F)C=C(N=2)C(F)F MDZCIAZOUBWBQP-UHFFFAOYSA-N 0.000 claims description 2
- LFARHAUIHDLASB-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-(difluoromethyl)-7-ethylimidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1CC)C=C(N=2)C(F)F LFARHAUIHDLASB-UHFFFAOYSA-N 0.000 claims description 2
- YZZCVOQEIYHQSP-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-(difluoromethyl)-7-propan-2-ylimidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1C(C)C)C=C(N=2)C(F)F YZZCVOQEIYHQSP-UHFFFAOYSA-N 0.000 claims description 2
- BYGSYURHBBKYPY-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-cyclopropyl-3-fluoro-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1C(F)(F)F)C(=C(N=2)C1CC1)F BYGSYURHBBKYPY-UHFFFAOYSA-N 0.000 claims description 2
- FDRAUUFYRYRYDU-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-cyclopropyl-7-(difluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)F)N=C(N=2)C1CC1 FDRAUUFYRYRYDU-UHFFFAOYSA-N 0.000 claims description 2
- NMAPCDXMWNNGPZ-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-cyclopropyl-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1C(F)(F)F)C=C(N=2)C1CC1 NMAPCDXMWNNGPZ-UHFFFAOYSA-N 0.000 claims description 2
- FGKWSXDBUIWSIM-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-ethyl-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)CC FGKWSXDBUIWSIM-UHFFFAOYSA-N 0.000 claims description 2
- GSAJTCMHWHHMGZ-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-ethyl-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1C(F)(F)F)C=C(N=2)CC GSAJTCMHWHHMGZ-UHFFFAOYSA-N 0.000 claims description 2
- VNAZQAPWLAHWHE-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-methyl-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C VNAZQAPWLAHWHE-UHFFFAOYSA-N 0.000 claims description 2
- FWQONIIKMFNLSW-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-propan-2-yl-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)(F)F)C=C(N=2)C(C)C FWQONIIKMFNLSW-UHFFFAOYSA-N 0.000 claims description 2
- JGISZJOLYYQLMF-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-2-propan-2-yl-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1C(F)(F)F)C=C(N=2)C(C)C JGISZJOLYYQLMF-UHFFFAOYSA-N 0.000 claims description 2
- HDXGBGGBLGZCQE-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-7-(difluoromethyl)-2-ethyl-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)F)N=C(N=2)CC HDXGBGGBLGZCQE-UHFFFAOYSA-N 0.000 claims description 2
- JSBWRTNBGLRLCE-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-7-cyclopropyl-2-(difluoromethyl)-5-methylimidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C(=NC=1C1CC1)C)C=C(N=2)C(F)F JSBWRTNBGLRLCE-UHFFFAOYSA-N 0.000 claims description 2
- BCNCAFSFNCDMSF-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-7-cyclopropyl-2-(difluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1C1CC1)C=C(N=2)C(F)F BCNCAFSFNCDMSF-UHFFFAOYSA-N 0.000 claims description 2
- ZNSAGOQLVSAEHJ-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-7-cyclopropyl-2-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1C1CC1)C=C(N=2)C(F)(F)F ZNSAGOQLVSAEHJ-UHFFFAOYSA-N 0.000 claims description 2
- XTTXMXSAKWBAPC-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-7-ethyl-2-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1CC)C=C(N=2)C(F)(F)F XTTXMXSAKWBAPC-UHFFFAOYSA-N 0.000 claims description 2
- CTRZTMXMDNBZNH-UHFFFAOYSA-N 8-(7-chloro-1H-indazol-5-yl)-7-methyl-2-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1C)C=C(N=2)C(F)(F)F CTRZTMXMDNBZNH-UHFFFAOYSA-N 0.000 claims description 2
- GCVHZDUWZBXAME-UHFFFAOYSA-N 8-(7-chloro-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-5-yl)-7-(4-fluorophenyl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound Fc1ccc(cc1)-c1ccn2nc(nc2c1C1CC2CNNC2C(Cl)C1)C(F)(F)F GCVHZDUWZBXAME-UHFFFAOYSA-N 0.000 claims description 2
- UPBKAPHFHRHOHO-UHFFFAOYSA-N 8-(7-fluoro-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-5-yl)-7-(4-fluorophenyl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound FC1CC(CC2CNNC12)c1c(ccn2nc(nc12)C(F)(F)F)-c1ccc(F)cc1 UPBKAPHFHRHOHO-UHFFFAOYSA-N 0.000 claims description 2
- VBSFFOIFHMUUMC-UHFFFAOYSA-N 8-(7-methyl-1H-indazol-5-yl)-2,7-bis(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound CC=1C=C(C=C2C=NNC=12)C=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C(F)(F)F VBSFFOIFHMUUMC-UHFFFAOYSA-N 0.000 claims description 2
- OQKRRNQBOKCULW-UHFFFAOYSA-N 8-(7-methyl-1H-indazol-5-yl)-2,7-bis(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound FC(C=1N=C2N(C=CC(=C2C=2C=C3C=NNC3=C(C=2)C)C(F)(F)F)C=1)(F)F OQKRRNQBOKCULW-UHFFFAOYSA-N 0.000 claims description 2
- CNKIQKJEZFHIGU-UHFFFAOYSA-N 8-(7-methyl-1H-indazol-5-yl)-2,7-bis(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound CC=1C=C(C=C2C=NNC=12)C=1C=2N(C=NC=1C(F)(F)F)C=C(N=2)C(F)(F)F CNKIQKJEZFHIGU-UHFFFAOYSA-N 0.000 claims description 2
- KJXALNSEDFUONF-UHFFFAOYSA-N 8-(7-methyl-1H-indazol-5-yl)-2-propan-2-yl-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C(C)(C)C1=NN2C(C(=C(C=C2)C(F)(F)F)C=2C=C3C=NNC3=C(C=2)C)=N1 KJXALNSEDFUONF-UHFFFAOYSA-N 0.000 claims description 2
- HQZGZMPQXZRVRQ-UHFFFAOYSA-N 8-(7-methyl-1H-indazol-5-yl)-2-propan-2-yl-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound C(C)(C)C=1N=C2N(C=CC(=C2C=2C=C3C=NNC3=C(C=2)C)C(F)(F)F)C=1 HQZGZMPQXZRVRQ-UHFFFAOYSA-N 0.000 claims description 2
- YNIPVXPGGAICFQ-UHFFFAOYSA-N 8-(7-methyl-1H-indazol-5-yl)-7-propan-2-yl-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C(C)(C)C1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C YNIPVXPGGAICFQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000010353 central nervous system vasculitis Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- 208000003926 Myelitis Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 83
- 239000003814 drug Substances 0.000 abstract description 13
- 238000000132 electrospray ionisation Methods 0.000 description 167
- 238000001819 mass spectrum Methods 0.000 description 163
- 238000005481 NMR spectroscopy Methods 0.000 description 146
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 140
- 235000019439 ethyl acetate Nutrition 0.000 description 70
- 239000000243 solution Substances 0.000 description 60
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 58
- 239000007787 solid Substances 0.000 description 46
- 238000006243 chemical reaction Methods 0.000 description 42
- 239000002904 solvent Substances 0.000 description 42
- 239000000460 chlorine Substances 0.000 description 41
- 230000002829 reductive effect Effects 0.000 description 40
- 238000011282 treatment Methods 0.000 description 39
- 239000011734 sodium Substances 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000000651 prodrug Substances 0.000 description 34
- 229940002612 prodrug Drugs 0.000 description 34
- 101100441092 Danio rerio crlf3 gene Proteins 0.000 description 31
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 30
- 125000001424 substituent group Chemical group 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 125000005843 halogen group Chemical group 0.000 description 28
- 150000002500 ions Chemical class 0.000 description 27
- 239000012267 brine Substances 0.000 description 25
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 24
- 229910004298 SiO 2 Inorganic materials 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 23
- WNAIFLGHMGJARG-UHFFFAOYSA-N 7-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-indazole Chemical compound C=1C=2C=NNC=2C(C)=CC=1B1OC(C)(C)C(C)(C)O1 WNAIFLGHMGJARG-UHFFFAOYSA-N 0.000 description 22
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 20
- 239000002207 metabolite Substances 0.000 description 20
- 239000000284 extract Substances 0.000 description 19
- 210000001320 hippocampus Anatomy 0.000 description 19
- 239000002253 acid Substances 0.000 description 18
- 239000010410 layer Substances 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 15
- 239000002585 base Substances 0.000 description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- KUFIOGDFEUKJFL-UHFFFAOYSA-N 8-chloro-7-iodo-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1I)N=C(N=2)C(F)(F)F KUFIOGDFEUKJFL-UHFFFAOYSA-N 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 230000000971 hippocampal effect Effects 0.000 description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- OIFCLSPBFZQITN-UHFFFAOYSA-N 7-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-indazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC(Cl)=C(NN=C2)C2=C1 OIFCLSPBFZQITN-UHFFFAOYSA-N 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- 206010010904 Convulsion Diseases 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 239000012041 precatalyst Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 8
- FNJJBYPHJOIJCL-UHFFFAOYSA-N 7-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydroindol-2-one Chemical compound C=1C=2CC(=O)NC=2C(C)=CC=1B1OC(C)(C)C(C)(C)O1 FNJJBYPHJOIJCL-UHFFFAOYSA-N 0.000 description 8
- 229940098747 AMPA receptor antagonist Drugs 0.000 description 8
- 239000000775 AMPA receptor antagonist Substances 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 108010032166 TARP Proteins 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 229930195712 glutamate Natural products 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- MAZRLHAJUPFISK-UHFFFAOYSA-N 3-bromo-1,1-difluoropropan-2-one Chemical compound FC(F)C(=O)CBr MAZRLHAJUPFISK-UHFFFAOYSA-N 0.000 description 7
- NINXGROOEMZYSZ-UHFFFAOYSA-N 3-chloro-4-(trifluoromethyl)pyridin-2-amine Chemical compound NC1=NC=CC(C(F)(F)F)=C1Cl NINXGROOEMZYSZ-UHFFFAOYSA-N 0.000 description 7
- RLGIUCPGZVWYRN-UHFFFAOYSA-N 8-bromo-2-cyclopropyl-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1C(F)(F)F)C=C(N=2)C1CC1 RLGIUCPGZVWYRN-UHFFFAOYSA-N 0.000 description 7
- VCEJOUNVWMWSAC-UHFFFAOYSA-N ClC=1C=C(C=C2CC(NC=12)=O)B1OC(C(O1)(C)C)(C)C Chemical compound ClC=1C=C(C=C2CC(NC=12)=O)B1OC(C(O1)(C)C)(C)C VCEJOUNVWMWSAC-UHFFFAOYSA-N 0.000 description 7
- 102000018899 Glutamate Receptors Human genes 0.000 description 7
- 108010027915 Glutamate Receptors Proteins 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- PDFCXUVNUUYYOI-UHFFFAOYSA-N 3-bromo-4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1Br PDFCXUVNUUYYOI-UHFFFAOYSA-N 0.000 description 6
- LPNHGKYSSUSNCU-UHFFFAOYSA-N 8-chloro-2,7-bis(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C(F)(F)F LPNHGKYSSUSNCU-UHFFFAOYSA-N 0.000 description 6
- KLDJMXVWNGEQCN-UHFFFAOYSA-N 8-chloro-7-(difluoromethyl)-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)F)N=C(N=2)C(F)(F)F KLDJMXVWNGEQCN-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- 125000006414 CCl Chemical group ClC* 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 102000004310 Ion Channels Human genes 0.000 description 6
- 108090000862 Ion Channels Proteins 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000012391 XPhos Pd G2 Substances 0.000 description 6
- 230000008485 antagonism Effects 0.000 description 6
- 239000001961 anticonvulsive agent Substances 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 150000002367 halogens Chemical group 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- WJYILVDGCNPKTL-UHFFFAOYSA-N 2-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC(C(F)(F)F)=CN21 WJYILVDGCNPKTL-UHFFFAOYSA-N 0.000 description 5
- HVTSDYOIOMBCFN-UHFFFAOYSA-N 8-bromo-7-methyl-2-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound BrC=1C=2N(C=CC=1C)C=C(N=2)C(F)(F)F HVTSDYOIOMBCFN-UHFFFAOYSA-N 0.000 description 5
- QBZONARKSKPJRS-UHFFFAOYSA-N 8-chloro-2-propan-2-yl-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C(C)C QBZONARKSKPJRS-UHFFFAOYSA-N 0.000 description 5
- 206010001497 Agitation Diseases 0.000 description 5
- 101000933374 Gallus gallus Brain-specific homeobox/POU domain protein 3 Proteins 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 230000000949 anxiolytic effect Effects 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- RSLSVURFMXHEEU-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[3-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylaniline Chemical compound [Pd+]Cl.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC(P(C2CCCCC2)C2CCCCC2)=C1 RSLSVURFMXHEEU-UHFFFAOYSA-M 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000002964 excitative effect Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- FEWLNYSYJNLUOO-UHFFFAOYSA-N 1-Piperidinecarboxaldehyde Chemical compound O=CN1CCCCC1 FEWLNYSYJNLUOO-UHFFFAOYSA-N 0.000 description 4
- CHZZGVOXBRLKIT-UHFFFAOYSA-N 2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=C(C(F)(F)F)N=C21 CHZZGVOXBRLKIT-UHFFFAOYSA-N 0.000 description 4
- WCCCDMWRBVVYCQ-UHFFFAOYSA-N 2-bromo-1-cyclopropylethanone Chemical compound BrCC(=O)C1CC1 WCCCDMWRBVVYCQ-UHFFFAOYSA-N 0.000 description 4
- ONZQYZKCUHFORE-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)CBr ONZQYZKCUHFORE-UHFFFAOYSA-N 0.000 description 4
- RYPIPAUETYMWCO-UHFFFAOYSA-N 5-bromo-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound NC1=NC=NC(C(F)(F)F)=C1Br RYPIPAUETYMWCO-UHFFFAOYSA-N 0.000 description 4
- CNOWTRSFMAQMKX-UHFFFAOYSA-N 7-chloro-8-iodo-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)I CNOWTRSFMAQMKX-UHFFFAOYSA-N 0.000 description 4
- HFCPBKAEEWKGNN-UHFFFAOYSA-N 8-chloro-2-ethyl-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)CC HFCPBKAEEWKGNN-UHFFFAOYSA-N 0.000 description 4
- 101000729818 Bacillus licheniformis Glutamate racemase Proteins 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 206010029350 Neurotoxicity Diseases 0.000 description 4
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000009460 calcium influx Effects 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 4
- 238000006880 cross-coupling reaction Methods 0.000 description 4
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000007135 neurotoxicity Effects 0.000 description 4
- 231100000228 neurotoxicity Toxicity 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 238000002603 single-photon emission computed tomography Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 210000000225 synapse Anatomy 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 108010072897 transcription factor Brn-2 Proteins 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- GTTQRVGVEIXEHQ-UHFFFAOYSA-N 3-chloro-4-iodopyridin-2-amine Chemical compound NC1=NC=CC(I)=C1Cl GTTQRVGVEIXEHQ-UHFFFAOYSA-N 0.000 description 3
- AMUOXBJQBLWWMS-UHFFFAOYSA-N 5-bromo-6-cyclopropyl-2-methylpyrimidin-4-amine Chemical compound CC1=NC(N)=C(Br)C(C2CC2)=N1 AMUOXBJQBLWWMS-UHFFFAOYSA-N 0.000 description 3
- JPSXIRLBBFYDEY-UHFFFAOYSA-N 5-bromo-6-cyclopropylpyrimidin-4-amine Chemical compound NC1=NC=NC(C2CC2)=C1Br JPSXIRLBBFYDEY-UHFFFAOYSA-N 0.000 description 3
- QKXISDUSLPVLLP-UHFFFAOYSA-N 5-bromo-6-ethylpyrimidin-4-amine Chemical compound CCC1=NC=NC(N)=C1Br QKXISDUSLPVLLP-UHFFFAOYSA-N 0.000 description 3
- CICPTJIUZQNCQR-UHFFFAOYSA-N 5-bromo-6-propan-2-ylpyrimidin-4-amine Chemical compound CC(C)C1=NC=NC(N)=C1Br CICPTJIUZQNCQR-UHFFFAOYSA-N 0.000 description 3
- FJSYORUXSNFTES-UHFFFAOYSA-N 8-bromo-2,7-bis(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1C(F)(F)F)C=C(N=2)C(F)(F)F FJSYORUXSNFTES-UHFFFAOYSA-N 0.000 description 3
- JJXXOVXJEHNNSX-UHFFFAOYSA-N 8-bromo-2-ethyl-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1C(F)(F)F)C=C(N=2)CC JJXXOVXJEHNNSX-UHFFFAOYSA-N 0.000 description 3
- JTWVEKOEVZTLRU-UHFFFAOYSA-N 8-bromo-2-propan-2-yl-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1C(F)(F)F)C=C(N=2)C(C)C JTWVEKOEVZTLRU-UHFFFAOYSA-N 0.000 description 3
- SHHFUNJOMAGCIT-UHFFFAOYSA-N 8-bromo-2-tert-butyl-7-methylimidazo[1,2-a]pyridine Chemical compound BrC=1C=2N(C=CC=1C)C=C(N=2)C(C)(C)C SHHFUNJOMAGCIT-UHFFFAOYSA-N 0.000 description 3
- SXUNDBKSHBSWJY-UHFFFAOYSA-N 8-bromo-7-cyclopropyl-5-methyl-2-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C(=NC=1C1CC1)C)C=C(N=2)C(F)(F)F SXUNDBKSHBSWJY-UHFFFAOYSA-N 0.000 description 3
- BRAKTQZIGJMQLL-UHFFFAOYSA-N 8-bromo-7-ethyl-2-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1CC)C=C(N=2)C(F)(F)F BRAKTQZIGJMQLL-UHFFFAOYSA-N 0.000 description 3
- YKKIRUQGEKHTKY-UHFFFAOYSA-N 8-bromo-7-methyl-2-phenylimidazo[1,2-a]pyridine Chemical compound BrC=1C=2N(C=CC=1C)C=C(N=2)C1=CC=CC=C1 YKKIRUQGEKHTKY-UHFFFAOYSA-N 0.000 description 3
- ZLGJRYXEEJFZBB-UHFFFAOYSA-N 8-bromo-7-methyl-2-propan-2-yl-[1,2,4]triazolo[1,5-a]pyridine Chemical compound BrC=1C=2N(C=CC=1C)N=C(N=2)C(C)C ZLGJRYXEEJFZBB-UHFFFAOYSA-N 0.000 description 3
- SVFZZSCFVFGTJE-UHFFFAOYSA-N 8-chloro-2,7-bis(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)(F)F)C=C(N=2)C(F)(F)F SVFZZSCFVFGTJE-UHFFFAOYSA-N 0.000 description 3
- OKBUFQXYMGFGHP-UHFFFAOYSA-N 8-chloro-2-cyclopropyl-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C1CC1 OKBUFQXYMGFGHP-UHFFFAOYSA-N 0.000 description 3
- UWXKJUKZQCSMIK-UHFFFAOYSA-N 8-chloro-2-cyclopropyl-7-iodo-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1I)N=C(N=2)C1CC1 UWXKJUKZQCSMIK-UHFFFAOYSA-N 0.000 description 3
- QTLAIWXKSBAMFI-UHFFFAOYSA-N 8-chloro-2-methyl-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C QTLAIWXKSBAMFI-UHFFFAOYSA-N 0.000 description 3
- TZEAUKSXXKUGBJ-UHFFFAOYSA-N 8-chloro-7-ethyl-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1CC)N=C(N=2)C(F)(F)F TZEAUKSXXKUGBJ-UHFFFAOYSA-N 0.000 description 3
- ONIBCCKEYURVLZ-UHFFFAOYSA-N 8-chloro-7-iodo-2-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound ClC=1C=2N(C=CC=1I)C=C(N=2)C(F)(F)F ONIBCCKEYURVLZ-UHFFFAOYSA-N 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- NIGHKBIGJKRDBS-UHFFFAOYSA-N CC1=C(C(=CC(=C1)C)C)S(=O)(=O)[O-].N[N+]1=C(C(=C(C=C1)I)Cl)N Chemical compound CC1=C(C(=CC(=C1)C)C)S(=O)(=O)[O-].N[N+]1=C(C(=C(C=C1)I)Cl)N NIGHKBIGJKRDBS-UHFFFAOYSA-N 0.000 description 3
- HPPXLRXHHGLCDJ-UHFFFAOYSA-N ClC1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NN(C2=C(C=1)C)COCC[Si](C)(C)C Chemical compound ClC1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NN(C2=C(C=1)C)COCC[Si](C)(C)C HPPXLRXHHGLCDJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000868545 Homo sapiens Voltage-dependent calcium channel gamma-8 subunit Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 102100032335 Voltage-dependent calcium channel gamma-8 subunit Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000004295 hippocampal neuron Anatomy 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- CSSYKHYGURSRAZ-UHFFFAOYSA-N methyl 2,2-difluoroacetate Chemical compound COC(=O)C(F)F CSSYKHYGURSRAZ-UHFFFAOYSA-N 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- NNTPEAXKKUPBHQ-UHFFFAOYSA-N 1-bromo-3-methylbutan-2-one Chemical compound CC(C)C(=O)CBr NNTPEAXKKUPBHQ-UHFFFAOYSA-N 0.000 description 2
- CCXQVBSQUQCEEO-UHFFFAOYSA-N 1-bromobutan-2-one Chemical compound CCC(=O)CBr CCXQVBSQUQCEEO-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- QPKMLEWZAVUIDT-UHFFFAOYSA-N 2-[(5-bromo-7-methylindazol-1-yl)methoxy]ethyl-trimethylsilane Chemical compound CC1=CC(Br)=CC2=C1N(COCC[Si](C)(C)C)N=C2 QPKMLEWZAVUIDT-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- ICPWFHKNYYRBSZ-UHFFFAOYSA-M 2-methoxypropanoate Chemical compound COC(C)C([O-])=O ICPWFHKNYYRBSZ-UHFFFAOYSA-M 0.000 description 2
- HICQYIDVMJLTRA-UHFFFAOYSA-N 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2h-indazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC2=C(F)NN=C2C=C1 HICQYIDVMJLTRA-UHFFFAOYSA-N 0.000 description 2
- WQYAZBFZFIUIPL-UHFFFAOYSA-N 3-fluoroazetidine Chemical compound FC1CNC1 WQYAZBFZFIUIPL-UHFFFAOYSA-N 0.000 description 2
- QBPYHICVLNIUPW-UHFFFAOYSA-N 3-iodo-4-methoxypyridin-2-amine Chemical compound COC1=CC=NC(N)=C1I QBPYHICVLNIUPW-UHFFFAOYSA-N 0.000 description 2
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 2
- BWMULFKDCVPGNF-UHFFFAOYSA-N 4-chloro-3-iodopyridin-2-amine Chemical compound NC1=NC=CC(Cl)=C1I BWMULFKDCVPGNF-UHFFFAOYSA-N 0.000 description 2
- QOICQCARYUIEJZ-UHFFFAOYSA-N 5-bromo-6-methylpyrimidin-4-amine Chemical compound CC1=NC=NC(N)=C1Br QOICQCARYUIEJZ-UHFFFAOYSA-N 0.000 description 2
- QTNYNHKPFHRQTB-UHFFFAOYSA-N 5-bromo-7-chloro-1,3-dihydroindol-2-one Chemical compound ClC1=CC(Br)=CC2=C1NC(=O)C2 QTNYNHKPFHRQTB-UHFFFAOYSA-N 0.000 description 2
- IQSRPQLSDHXAIZ-UHFFFAOYSA-N 5-bromo-7-chloro-1h-indazole Chemical compound ClC1=CC(Br)=CC2=C1NN=C2 IQSRPQLSDHXAIZ-UHFFFAOYSA-N 0.000 description 2
- ONFYELNCLOYDDR-UHFFFAOYSA-N 5-bromo-7-methoxy-1H-indole-2,3-dione Chemical compound BrC=1C=C2C(C(NC2=C(C1)OC)=O)=O ONFYELNCLOYDDR-UHFFFAOYSA-N 0.000 description 2
- OUNQFZFHLJLFAR-UHFFFAOYSA-N 5-bromo-7-methyl-1h-indazole Chemical compound CC1=CC(Br)=CC2=C1NN=C2 OUNQFZFHLJLFAR-UHFFFAOYSA-N 0.000 description 2
- FIAIKJQZLXLGCR-UHFFFAOYSA-N 6-(trifluoromethyl)pyrimidin-4-amine Chemical compound NC1=CC(C(F)(F)F)=NC=N1 FIAIKJQZLXLGCR-UHFFFAOYSA-N 0.000 description 2
- ZYBYKEGJAYXQKM-UHFFFAOYSA-N 7-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydroindol-2-one Chemical compound O1C(C)(C)C(C)(C)OB1C(C=C1F)=CC2=C1NC(=O)C2 ZYBYKEGJAYXQKM-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- JHPMQXRFVQRFSD-UHFFFAOYSA-N 8-bromo-2-(difluoromethyl)-7-ethylimidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1CC)C=C(N=2)C(F)F JHPMQXRFVQRFSD-UHFFFAOYSA-N 0.000 description 2
- ADQWJDNHFGGUPN-UHFFFAOYSA-N 8-bromo-2-(difluoromethyl)-7-propan-2-ylimidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1C(C)C)C=C(N=2)C(F)F ADQWJDNHFGGUPN-UHFFFAOYSA-N 0.000 description 2
- PUGWIVDXQZGENX-UHFFFAOYSA-N 8-bromo-2-cyclopropyl-3-fluoro-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1C(F)(F)F)C(=C(N=2)C1CC1)F PUGWIVDXQZGENX-UHFFFAOYSA-N 0.000 description 2
- RLZVEHILBFBUAI-UHFFFAOYSA-N 8-bromo-2-cyclopropyl-7-methylimidazo[1,2-a]pyridine Chemical compound BrC=1C=2N(C=CC=1C)C=C(N=2)C1CC1 RLZVEHILBFBUAI-UHFFFAOYSA-N 0.000 description 2
- PTZPZSPEMMPNCC-UHFFFAOYSA-N 8-bromo-3-chloro-2-cyclopropyl-7-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1C(F)(F)F)C(=C(N=2)C1CC1)Cl PTZPZSPEMMPNCC-UHFFFAOYSA-N 0.000 description 2
- DXNJDNKFXANAJV-UHFFFAOYSA-N 8-bromo-7-cyclopropyl-2-(difluoromethyl)-5-methylimidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C(=NC=1C1CC1)C)C=C(N=2)C(F)F DXNJDNKFXANAJV-UHFFFAOYSA-N 0.000 description 2
- MYCOCESRNFUTPS-UHFFFAOYSA-N 8-bromo-7-cyclopropyl-2-(difluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1C1CC1)C=C(N=2)C(F)F MYCOCESRNFUTPS-UHFFFAOYSA-N 0.000 description 2
- VJFMZJRVZARDGL-UHFFFAOYSA-N 8-bromo-7-cyclopropyl-2-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1C1CC1)C=C(N=2)C(F)(F)F VJFMZJRVZARDGL-UHFFFAOYSA-N 0.000 description 2
- DVDAYTJABFTSBZ-UHFFFAOYSA-N 8-bromo-7-methyl-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound BrC=1C=2N(C=CC=1C)N=C(N=2)C(F)(F)F DVDAYTJABFTSBZ-UHFFFAOYSA-N 0.000 description 2
- OSJLYCLSOBALKW-UHFFFAOYSA-N 8-bromo-7-methyl-2-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1C)C=C(N=2)C(F)(F)F OSJLYCLSOBALKW-UHFFFAOYSA-N 0.000 description 2
- GSCIXCUKGVSRSS-UHFFFAOYSA-N 8-bromo-7-propan-2-yl-2-(trifluoromethyl)imidazo[1,2-c]pyrimidine Chemical compound BrC=1C=2N(C=NC=1C(C)C)C=C(N=2)C(F)(F)F GSCIXCUKGVSRSS-UHFFFAOYSA-N 0.000 description 2
- OVBGWUWUQUOFHS-UHFFFAOYSA-N 8-chloro-2-(difluoromethyl)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C(F)F OVBGWUWUQUOFHS-UHFFFAOYSA-N 0.000 description 2
- WVRGDQUJHBEUHU-UHFFFAOYSA-N 8-chloro-2-(difluoromethyl)-7-iodo-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1I)N=C(N=2)C(F)F WVRGDQUJHBEUHU-UHFFFAOYSA-N 0.000 description 2
- SNPMIMLCEVFIDM-UHFFFAOYSA-N 8-chloro-2-cyclobutyl-7-iodo-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1I)N=C(N=2)C1CCC1 SNPMIMLCEVFIDM-UHFFFAOYSA-N 0.000 description 2
- ZZBKOLOJVADGBC-UHFFFAOYSA-N 8-chloro-2-cyclopentyl-7-iodo-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1I)N=C(N=2)C1CCCC1 ZZBKOLOJVADGBC-UHFFFAOYSA-N 0.000 description 2
- INGJGLYUUYGJKW-UHFFFAOYSA-N 8-chloro-7-iodo-2-(methoxymethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1I)N=C(N=2)COC INGJGLYUUYGJKW-UHFFFAOYSA-N 0.000 description 2
- NOEXHOFWRLILGY-UHFFFAOYSA-N 8-chloro-7-iodo-2-methyl-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1I)N=C(N=2)C NOEXHOFWRLILGY-UHFFFAOYSA-N 0.000 description 2
- SFEARHCUEJFXLD-UHFFFAOYSA-N 8-chloro-7-iodo-2-propan-2-yl-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1I)N=C(N=2)C(C)C SFEARHCUEJFXLD-UHFFFAOYSA-N 0.000 description 2
- YHUJTKMAAAZCNM-UHFFFAOYSA-N 8-iodo-7-methoxy-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound IC=1C=2N(C=CC=1OC)N=C(N=2)C(F)(F)F YHUJTKMAAAZCNM-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- BKUJJUFNTYIDPI-UHFFFAOYSA-N BrC=1C=C2CC(NC2=C(C=1)OC)=O Chemical compound BrC=1C=C2CC(NC2=C(C=1)OC)=O BKUJJUFNTYIDPI-UHFFFAOYSA-N 0.000 description 2
- 239000012388 BrettPhos 3rd generation precatalyst Substances 0.000 description 2
- AMZXYXJYPNFEHJ-UHFFFAOYSA-N CC1(OB(OC1(C)C)C=1C=C2CC(NC2=C(C=1)OC)=O)C Chemical compound CC1(OB(OC1(C)C)C=1C=C2CC(NC2=C(C=1)OC)=O)C AMZXYXJYPNFEHJ-UHFFFAOYSA-N 0.000 description 2
- RRWHHYBYWAQALO-UHFFFAOYSA-N CC1=C(C(=CC(=C1)C)C)S(=O)(=O)[O-].N[N+]1=C(C(=C(C=C1)C)Br)N Chemical compound CC1=C(C(=CC(=C1)C)C)S(=O)(=O)[O-].N[N+]1=C(C(=C(C=C1)C)Br)N RRWHHYBYWAQALO-UHFFFAOYSA-N 0.000 description 2
- PBHORWARFJHKIS-UHFFFAOYSA-N CC=1C=C(C=C2C=NN(C=12)COCC[Si](C)(C)C)B1OC(C(O1)(C)C)(C)C Chemical compound CC=1C=C(C=C2C=NN(C=12)COCC[Si](C)(C)C)B1OC(C(O1)(C)C)(C)C PBHORWARFJHKIS-UHFFFAOYSA-N 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- UAVUKIODUPLRCS-UHFFFAOYSA-N ClC=1C=2N(C=CC=1C=C)N=C(N=2)C(F)(F)F Chemical compound ClC=1C=2N(C=CC=1C=C)N=C(N=2)C(F)(F)F UAVUKIODUPLRCS-UHFFFAOYSA-N 0.000 description 2
- JRDKFHBQMDRHJV-UHFFFAOYSA-N ClC=1C=2N(C=CC=1C=O)N=C(N=2)C(F)(F)F Chemical compound ClC=1C=2N(C=CC=1C=O)N=C(N=2)C(F)(F)F JRDKFHBQMDRHJV-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- OLEVUJIRECLBLF-UHFFFAOYSA-N FC(C1=C(C(F)(F)F)N=C2N1C=CC=C2)(F)F Chemical compound FC(C1=C(C(F)(F)F)N=C2N1C=CC=C2)(F)F OLEVUJIRECLBLF-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 102100030651 Glutamate receptor 2 Human genes 0.000 description 2
- 101710087631 Glutamate receptor 2 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 2
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 0 O=C(C1)*c(c(Cl)c2)c1cc2I Chemical compound O=C(C1)*c(c(Cl)c2)c1cc2I 0.000 description 2
- 102000002512 Orexin Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- CHKQALUEEULCPZ-UHFFFAOYSA-N amino 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S(=O)(=O)ON)C(C)=C1 CHKQALUEEULCPZ-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- VQFAIAKCILWQPZ-UHFFFAOYSA-N bromoacetone Chemical compound CC(=O)CBr VQFAIAKCILWQPZ-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- UZBHNSVUMGIKLU-UHFFFAOYSA-N cyclopenten-1-ylboronic acid Chemical compound OB(O)C1=CCCC1 UZBHNSVUMGIKLU-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 208000028329 epileptic seizure Diseases 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Chemical group 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000011630 iodine Chemical group 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- GQJCAQADCPTHKN-UHFFFAOYSA-N methyl 2,2-difluoro-2-fluorosulfonylacetate Chemical compound COC(=O)C(F)(F)S(F)(=O)=O GQJCAQADCPTHKN-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- MCECSFFXUPEPDB-UHFFFAOYSA-N n-[6-(2-methylpyrazol-3-yl)-2,4-dioxo-7-propan-2-yl-1h-quinazolin-3-yl]methanesulfonamide Chemical compound CC(C)C1=CC=2NC(=O)N(NS(C)(=O)=O)C(=O)C=2C=C1C1=CC=NN1C MCECSFFXUPEPDB-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000008587 neuronal excitability Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 108060005714 orexin Proteins 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000031877 prophase Effects 0.000 description 2
- 238000013138 pruning Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012363 selectfluor Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000009782 synaptic response Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 238000003354 tissue distribution assay Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- YGGMQWSJXSNGDT-UHFFFAOYSA-N (4-fluorophenyl)boron Chemical compound [B]C1=CC=C(F)C=C1 YGGMQWSJXSNGDT-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- PTQROAOBTCPDPA-UHFFFAOYSA-N 1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole Chemical compound O1C(C)(C)C(C)(C)OB1N1C2=CC=CC=C2C=N1 PTQROAOBTCPDPA-UHFFFAOYSA-N 0.000 description 1
- SAIRZMWXVJEBMO-UHFFFAOYSA-N 1-bromo-3,3-dimethylbutan-2-one Chemical compound CC(C)(C)C(=O)CBr SAIRZMWXVJEBMO-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- WTTFDUBNZVZOQH-UHFFFAOYSA-N 2-(difluoromethyl)-8-(7-methyl-1H-indazol-5-yl)-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound FC(C=1N=C2N(C=CC(=C2C=2C=C3C=NNC3=C(C=2)C)C(F)(F)F)C=1)F WTTFDUBNZVZOQH-UHFFFAOYSA-N 0.000 description 1
- OIWHGYGUHGWJOI-UHFFFAOYSA-N 2-ethyl-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=C(CC)N=C21 OIWHGYGUHGWJOI-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- TWBPWBPGNQWFSJ-UHFFFAOYSA-N 2-phenylaniline Chemical group NC1=CC=CC=C1C1=CC=CC=C1 TWBPWBPGNQWFSJ-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HYHNPUGUPISSQO-FYWRMAATSA-N 3-(2-chlorophenyl)-2-[(e)-2-[6-(diethylaminomethyl)pyridin-2-yl]ethenyl]-6-fluoroquinazolin-4-one Chemical compound CCN(CC)CC1=CC=CC(\C=C\C=2N(C(=O)C3=CC(F)=CC=C3N=2)C=2C(=CC=CC=2)Cl)=N1 HYHNPUGUPISSQO-FYWRMAATSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NPDICENVXROWJV-UHFFFAOYSA-N 3-chloro-2-fluoro-4-iodopyridine Chemical compound FC1=NC=CC(I)=C1Cl NPDICENVXROWJV-UHFFFAOYSA-N 0.000 description 1
- YNYROPYZSZBORI-UHFFFAOYSA-N 3-chloro-4-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=NC=C1Cl YNYROPYZSZBORI-UHFFFAOYSA-N 0.000 description 1
- PXFUWRWCKSLCLS-UHFFFAOYSA-N 3-fluoroazetidine;hydron;chloride Chemical compound Cl.FC1CNC1 PXFUWRWCKSLCLS-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical compound OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 description 1
- 239000003140 4 aminobutyric acid A receptor blocking agent Substances 0.000 description 1
- 239000003483 4 aminobutyric acid A receptor stimulating agent Substances 0.000 description 1
- MECCSFDHAVAAAW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-propan-2-yl-1,3,2-dioxaborolane Chemical compound CC(C)B1OC(C)(C)C(C)(C)O1 MECCSFDHAVAAAW-UHFFFAOYSA-N 0.000 description 1
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 description 1
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-M 4-methoxybenzoate Chemical compound COC1=CC=C(C([O-])=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-M 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- YGAXEFQRZVEQAZ-UHFFFAOYSA-N 5-bromo-3-fluoro-2h-indazole Chemical compound C1=C(Br)C=C2C(F)=NNC2=C1 YGAXEFQRZVEQAZ-UHFFFAOYSA-N 0.000 description 1
- WWYUGKFXALMFOC-UHFFFAOYSA-N 5-bromo-7-fluoro-1,3-dihydroindol-2-one Chemical compound FC1=CC(Br)=CC2=C1NC(=O)C2 WWYUGKFXALMFOC-UHFFFAOYSA-N 0.000 description 1
- MZNDURZLKXBGAU-UHFFFAOYSA-N 5-bromo-7-methyl-1,3-dihydroindol-2-one Chemical compound CC1=CC(Br)=CC2=C1NC(=O)C2 MZNDURZLKXBGAU-UHFFFAOYSA-N 0.000 description 1
- HECJMTPEVWQFCY-UHFFFAOYSA-N 6-bromo-3h-1,3-benzothiazol-2-one Chemical compound BrC1=CC=C2NC(=O)SC2=C1 HECJMTPEVWQFCY-UHFFFAOYSA-N 0.000 description 1
- TXJQTGKSJVQERW-UHFFFAOYSA-N 6-cyclopropyl-2-methylpyrimidin-4-amine Chemical compound CC1=NC(N)=CC(C2CC2)=N1 TXJQTGKSJVQERW-UHFFFAOYSA-N 0.000 description 1
- HYXLQVUEUHPYGV-UHFFFAOYSA-N 6-cyclopropylpyrimidin-4-amine Chemical compound C1=NC(N)=CC(C2CC2)=N1 HYXLQVUEUHPYGV-UHFFFAOYSA-N 0.000 description 1
- UOMLWNRTYQTWFT-UHFFFAOYSA-N 6-ethylpyrimidin-4-amine Chemical compound CCC1=CC(N)=NC=N1 UOMLWNRTYQTWFT-UHFFFAOYSA-N 0.000 description 1
- LAERIBHKDNBVOO-UHFFFAOYSA-N 6-methylpyrimidin-4-amine Chemical compound CC1=CC(N)=NC=N1 LAERIBHKDNBVOO-UHFFFAOYSA-N 0.000 description 1
- ZVKFQZPWQXBUOJ-UHFFFAOYSA-N 6-propan-2-ylpyrimidin-4-amine Chemical compound CC(C)C1=CC(N)=NC=N1 ZVKFQZPWQXBUOJ-UHFFFAOYSA-N 0.000 description 1
- FPDLUAACCNVSQA-UHFFFAOYSA-N 7-chloro-1,3-dihydroindol-2-one Chemical compound ClC1=CC=CC2=C1NC(=O)C2 FPDLUAACCNVSQA-UHFFFAOYSA-N 0.000 description 1
- KVTNPWPUZLNPFN-UHFFFAOYSA-N 7-chloro-5-[2-(difluoromethyl)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-1,3-dihydroindol-2-one Chemical compound ClC=1C=C(C=C2CC(NC=12)=O)C=1C=2N(C=CC=1C(F)(F)F)N=C(N=2)C(F)F KVTNPWPUZLNPFN-UHFFFAOYSA-N 0.000 description 1
- HVEULDUNYUCHBM-UHFFFAOYSA-N 7-chloro-8-iodo-2-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC(Cl)=C(I)C2=NC(C(F)(F)F)=CN21 HVEULDUNYUCHBM-UHFFFAOYSA-N 0.000 description 1
- URXIUXOJSICGOD-UHFFFAOYSA-N 7-methoxy-1h-indole-2,3-dione Chemical compound COC1=CC=CC2=C1NC(=O)C2=O URXIUXOJSICGOD-UHFFFAOYSA-N 0.000 description 1
- FERQNIIXUJRFOL-UHFFFAOYSA-N 7-methyl-8-(7-methyl-1H-indazol-5-yl)-2-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound CC1=C(C=2N(C=C1)C=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C FERQNIIXUJRFOL-UHFFFAOYSA-N 0.000 description 1
- WLEYTVZOWDOFEQ-UHFFFAOYSA-N 8-chloro-2-(difluoromethyl)-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)(F)F)C=C(N=2)C(F)F WLEYTVZOWDOFEQ-UHFFFAOYSA-N 0.000 description 1
- ULQUHMWRBNXJND-UHFFFAOYSA-N 8-chloro-2-cyclopropyl-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)(F)F)C=C(N=2)C1CC1 ULQUHMWRBNXJND-UHFFFAOYSA-N 0.000 description 1
- WGWONHBIYQGXCZ-UHFFFAOYSA-N 8-chloro-2-ethyl-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)(F)F)C=C(N=2)CC WGWONHBIYQGXCZ-UHFFFAOYSA-N 0.000 description 1
- YMMLWTBMFPNFPO-UHFFFAOYSA-N 8-chloro-2-ethyl-7-iodo-[1,2,4]triazolo[1,5-a]pyridine Chemical compound ClC=1C=2N(C=CC=1I)N=C(N=2)CC YMMLWTBMFPNFPO-UHFFFAOYSA-N 0.000 description 1
- CXHOFRYCZYITBG-UHFFFAOYSA-N 8-chloro-2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)(F)F)C=C(N=2)C CXHOFRYCZYITBG-UHFFFAOYSA-N 0.000 description 1
- FYXILWLUUQCJPA-UHFFFAOYSA-N 8-chloro-2-propan-2-yl-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound ClC=1C=2N(C=CC=1C(F)(F)F)C=C(N=2)C(C)C FYXILWLUUQCJPA-UHFFFAOYSA-N 0.000 description 1
- DTYFNLFSQNGRRQ-UHFFFAOYSA-N 8-chloro-7-ethyl-2-iodo-[1,2,4]triazolo[1,5-a]pyridine Chemical compound CCC1=C(C2=NC(=NN2C=C1)I)Cl DTYFNLFSQNGRRQ-UHFFFAOYSA-N 0.000 description 1
- FGLMNCMFIPSSBN-UHFFFAOYSA-N 8-iodo-7-methoxy-2-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound IC=1C=2N(C=CC=1OC)C=C(N=2)C(F)(F)F FGLMNCMFIPSSBN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- PVTTVNFNIYSGOM-UHFFFAOYSA-N C1(=CCCC1)C1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C Chemical compound C1(=CCCC1)C1=C(C=2N(C=C1)N=C(N=2)C(F)(F)F)C=1C=C2C=NNC2=C(C=1)C PVTTVNFNIYSGOM-UHFFFAOYSA-N 0.000 description 1
- DNQGNEAQEFADMR-UHFFFAOYSA-N C1=C(C=C(C2=C1C=NN2)Cl)C3=NC(=CC(=N3)N)C(F)(F)F Chemical compound C1=C(C=C(C2=C1C=NN2)Cl)C3=NC(=CC(=N3)N)C(F)(F)F DNQGNEAQEFADMR-UHFFFAOYSA-N 0.000 description 1
- RPBDCDQMCRHNLM-UHFFFAOYSA-N C1=NNC=C2C=CC=CC2=C1 Chemical compound C1=NNC=C2C=CC=CC2=C1 RPBDCDQMCRHNLM-UHFFFAOYSA-N 0.000 description 1
- ABWPKMUSJKXSRN-UHFFFAOYSA-N CC1(OB(OC1(C)C)C1=CC2=C(N(C(S2)=O)COCC[Si](C)(C)C)C=C1)C Chemical compound CC1(OB(OC1(C)C)C1=CC2=C(N(C(S2)=O)COCC[Si](C)(C)C)C=C1)C ABWPKMUSJKXSRN-UHFFFAOYSA-N 0.000 description 1
- HSGHZPIFWODHRT-UHFFFAOYSA-N CC1=CC(c(c2nc(C(F)F)n[n]2cc2)c2-c(cc2)ccc2F)=CC2C1=NN=C2 Chemical compound CC1=CC(c(c2nc(C(F)F)n[n]2cc2)c2-c(cc2)ccc2F)=CC2C1=NN=C2 HSGHZPIFWODHRT-UHFFFAOYSA-N 0.000 description 1
- XSQCFEWSLZFNDD-UHFFFAOYSA-N CC=1C=C(C=C2C=NN(C=12)COCC[Si](C)(C)C)C=1C(=NC=NC=1C(F)(F)F)N Chemical compound CC=1C=C(C=C2C=NN(C=12)COCC[Si](C)(C)C)C=1C(=NC=NC=1C(F)(F)F)N XSQCFEWSLZFNDD-UHFFFAOYSA-N 0.000 description 1
- LRAHXTVQASONBK-UHFFFAOYSA-N CC=1C=C(C=C2C=NN(C=12)COCC[Si](C)(C)C)C=1C=2N(C=CC=1C#N)N=C(N=2)C(F)(F)F Chemical compound CC=1C=C(C=C2C=NN(C=12)COCC[Si](C)(C)C)C=1C=2N(C=CC=1C#N)N=C(N=2)C(F)(F)F LRAHXTVQASONBK-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- YNCCDZORKNMPGT-UHFFFAOYSA-N Cc1c2[nH]ncc2cc(I)c1 Chemical compound Cc1c2[nH]ncc2cc(I)c1 YNCCDZORKNMPGT-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- WROCMGXLEVEJHC-UHFFFAOYSA-N ClC=1C=2N(C=CC=1C1=CC=C(C=C1)F)C=C(N=2)C(F)(F)F Chemical compound ClC=1C=2N(C=CC=1C1=CC=C(C=C1)F)C=C(N=2)C(F)(F)F WROCMGXLEVEJHC-UHFFFAOYSA-N 0.000 description 1
- FWEQDZPBSVLEAT-UHFFFAOYSA-N ClC=1C=2N(C=CC=1C1=CC=C(C=C1)F)N=C(N=2)C1CCC1 Chemical compound ClC=1C=2N(C=CC=1C1=CC=C(C=C1)F)N=C(N=2)C1CCC1 FWEQDZPBSVLEAT-UHFFFAOYSA-N 0.000 description 1
- IOSKSEXTHRFRNL-UHFFFAOYSA-N ClC=1C=C(C=C2C=NNC=12)C=1C(=NC=NC=1C(F)(F)F)N Chemical compound ClC=1C=C(C=C2C=NNC=12)C=1C(=NC=NC=1C(F)(F)F)N IOSKSEXTHRFRNL-UHFFFAOYSA-N 0.000 description 1
- TZBKZYKDFMZFCW-UHFFFAOYSA-N Clc1cc(I)cc2c1[nH]nc2 Chemical compound Clc1cc(I)cc2c1[nH]nc2 TZBKZYKDFMZFCW-UHFFFAOYSA-N 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCMXFZIZHXFNFH-UHFFFAOYSA-N FC(c1n[n](ccc(-c(cc2)ccc2F)c2-c(cc3Cl)cc4c3[nH]nc4)c2n1)(F)F Chemical compound FC(c1n[n](ccc(-c(cc2)ccc2F)c2-c(cc3Cl)cc4c3[nH]nc4)c2n1)(F)F KCMXFZIZHXFNFH-UHFFFAOYSA-N 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 102100030652 Glutamate receptor 1 Human genes 0.000 description 1
- 101710087628 Glutamate receptor 1 Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 101000584505 Homo sapiens Synaptic vesicle glycoprotein 2A Proteins 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZICGQEKEQMPOFW-UHFFFAOYSA-N O=C(C1)Nc(c(F)c2)c1cc2I Chemical compound O=C(C1)Nc(c(F)c2)c1cc2I ZICGQEKEQMPOFW-UHFFFAOYSA-N 0.000 description 1
- ULGPOGHGUJIZFW-UHFFFAOYSA-N OC(C1)Nc(c(Cl)c2)c1cc2-c1c(C(F)F)cc[n]2nc(C(F)(F)F)nc12 Chemical compound OC(C1)Nc(c(Cl)c2)c1cc2-c1c(C(F)F)cc[n]2nc(C(F)(F)F)nc12 ULGPOGHGUJIZFW-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- JXDYKVIHCLTXOP-UHFFFAOYSA-N Pseudoisatin Natural products C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000010357 RNA editing Methods 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 206010040703 Simple partial seizures Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102100030701 Synaptic vesicle glycoprotein 2A Human genes 0.000 description 1
- 108090000030 T-Type Calcium Channels Proteins 0.000 description 1
- 102000003691 T-Type Calcium Channels Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical class NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- MMCOUVMKNAHQOY-UHFFFAOYSA-N carbonoperoxoic acid Chemical class OOC(O)=O MMCOUVMKNAHQOY-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 229940125400 channel inhibitor Drugs 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- INVYSLWXPIEDIQ-UHFFFAOYSA-N cyclobutanecarbaldehyde Chemical compound O=CC1CCC1 INVYSLWXPIEDIQ-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PSHRANCNVXNITH-UHFFFAOYSA-N dimethylamino acetate Chemical compound CN(C)OC(C)=O PSHRANCNVXNITH-UHFFFAOYSA-N 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-M ethanimidate Chemical compound CC([O-])=N DLFVBJFMPXGRIB-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- GZKHDVAKKLTJPO-UHFFFAOYSA-N ethyl 2,2-difluoroacetate Chemical compound CCOC(=O)C(F)F GZKHDVAKKLTJPO-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000009206 glutamatergic signaling Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- PQWQQQGKMHENOC-UHFFFAOYSA-N imidazo[1,2-c]pyrimidine Chemical compound C1=NC=CC2=NC=CN21 PQWQQQGKMHENOC-UHFFFAOYSA-N 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 125000001905 inorganic group Chemical group 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- DUWKUHWHTPRMAP-UHFFFAOYSA-N n-ethyl-1,2-dimethyl-6-methylimino-n-phenylpyrimidin-4-amine;hydron;chloride Chemical compound Cl.C=1C(=NC)N(C)C(C)=NC=1N(CC)C1=CC=CC=C1 DUWKUHWHTPRMAP-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- VLZLOWPYUQHHCG-UHFFFAOYSA-N nitromethylbenzene Chemical compound [O-][N+](=O)CC1=CC=CC=C1 VLZLOWPYUQHHCG-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N ortho-methoxybenzoic acid Natural products COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 125000005541 phosphonamide group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000664 voltage gated sodium channel blocking agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
Abstract
Description
本出願は、参照により本明細書に組み込まれている、2016年10月26日に出願された米国特許出願公開第62/412,867号からの優先権を主張するものである。
本発明は、AMPA受容体調節特性を有する化合物、これらの化合物を含む医薬組成物、これらの化合物を調製するための化学プロセス、及び動物、特にヒトにおけるAMPA受容体活性に関連する疾患の治療におけるその使用に関する。
Xは、N又はCHであり、
Yは、N、CH、CF、及びCClからなる群から選択され、
R1は、H、ハロ、及びCH3からなる群から選択され、
R2は、C1〜6アルキル、C1〜6ハロアルキル、C1〜6アルコキシ、C3〜8シクロアルキル及びフェニルからなる群から選択され、
R3は、H、ハロ、CH3及びCF3からなる群から選択され、
R4は、C1〜6アルキル、C1〜6ハロアルキル、C1〜6アルコキシ、Fで置換されたフェニル、及びピリジルからなる群から選択され、
Xは、N又はCHであり、
Yは、N、CH、CF、及びCClからなる群から選択され、
R1は、H、ハロ、及びCH3からなる群から選択され、
R2は、C1〜6アルキル、C1〜6ハロアルキル、C1〜6アルコキシ、C3〜8シクロアルキル及びフェニルからなる群から選択され、
R3は、H、ハロ、CH3及びCF3からなる群から選択され、
R4は、ハロ、C1〜6アルキル、C1〜6アルコキシ、C1〜6ハロアルキル、CN、C3〜8シクロアルキル、アゼチジニル、Fで置換されたアゼチジニル、及びFで置換されたフェニルからなる群から選択され、
R1は、Hであり、
R2は、C1〜6アルキル、C1〜6ハロアルキル、CH2OCH3、C3〜8シクロアルキルからなる群から選択され、
R4は、ハロ、C1〜6アルキル、C1〜6アルコキシ、C1〜6ハロアルキル、CN、C3〜8シクロアルキル、アゼチジニル、Fで置換されたアゼチジニル、及びFで置換されたフェニルからなる群から選択され、
R5は、
R1は、Hであり、
R2は、C1〜6アルキル、C1〜6ハロアルキル、CH2OCH3、C3〜8シクロアルキル及びフェニルからなる群から選択され、
R4は、ハロ、C1〜6アルキル、C1〜6アルコキシ、C1〜6ハロアルキル、CN、C3〜8シクロアルキル、アゼチジニル、Fで置換されたアゼチジニル、及びFで置換されたフェニルからなる群から選択され、
R5は、
Yは、CH、CF、及びCClからなる群から選択され、
R1は、H又はCH3であり、
R2は、C1〜6アルキル、C1〜6ハロアルキル、CH2OCH3、C3〜8シクロアルキル及びフェニルからなる群から選択され、
R4は、ハロ、C1〜6アルキル、C1〜6アルコキシ、C1〜6ハロアルキル、CN、C3〜8シクロアルキル、アゼチジニル、Fで置換されたアゼチジニル、及びFで置換されたフェニルからなる群から選択され、
R5は、
(A)有効量の式(I):
Xは、N又はCHであり、
Yは、N、CH、CF、及びCClからなる群から選択され、
R1は、H又はCH3であり、
R2は、C1〜6アルキル、C1〜6ハロアルキル、CH2OCH3、C3〜8シクロアルキル及びフェニルからなる群から選択され、
R3は、H、ハロ、CH3及びCF3からなる群から選択され、
R4は、ハロ、C1〜6アルキル、C1〜6アルコキシ、C1〜6ハロアルキル、CN、C3〜8シクロアルキル、アゼチジニル、Fで置換されたアゼチジニル、及びFで置換されたフェニルからなる群から選択され、
式(I)の化合物の製薬上許容される塩、N−酸化物又は溶媒和物と、
(B)少なくとも1つの製薬上許容される賦形剤と、
を含む医薬組成物。
Xは、N又はCHであり、
Yは、N、CH、CF、及びCClからなる群から選択され、
R1は、H又はCH3であり、
R2は、C1〜6アルキル、C1〜6ハロアルキル、CH2OCH3、C3〜8シクロアルキル及びフェニルからなる群から選択され、
R3は、H、ハロ、CH3及びCF3からなる群から選択され、
R4は、ハロ、C1〜6アルキル、C1〜6アルコキシ、C1〜6ハロアルキル、CN、C3〜8シクロアルキル、アゼチジニル、Fで置換されたアゼチジニル、及びFで置換されたフェニルからなる群から選択され、
その製薬上許容される塩、N−酸化物、又は溶媒和物から選択される少なくとも1つの化合物を投与することを含む、方法である。
本明細書で使用するとき、「含む(including)」、「含有する(containing)」、及び「含む(comprising)」という用語を本明細書では幅広い非限定的意味で用いる。
表3.本明細書で使用される略語及び頭字語としては、以下が挙げられる。
次に、本発明の方法において有用な例示的な化合物を、以下のその一般的調製についての例示的な合成スキーム及び以下の具体例を参照することによって説明する。
Xterra Prep RP18カラム(5μM、30×100又は50×150mm)又はXBridge 18C OBDカラム(5μM、30×100又は50×150mm)を使用してAgilent HPLC上で行い、40又は80mL/分の流速で、5% ACN/20mM NH4OHの移動相を2分間保持してから5〜99%のACN勾配を15分間かけて送液した後、99% ACNで5分間保持した。
又は
Shimadzu LC−8AシリーズHPLCで、Inertsil ODS−3カラム(3μm、30×100mm、T=45℃)を使用し、80mL/分の流速で、H2O中5% ACN(いずれも0.05% TFAを含む)の移動相を1分間保持、次に、6分間かけて5〜99%のACN勾配で変化し、次に、99% ACNで3分間保持する、
又は
Shimadzu LC−8AシリーズHPLCで、XBridge C18 OBDカラム(5μm、50×100mm)を使用し、80mL/分の流速で、H2O中5% ACN(いずれも0.05% TFAを含む)の移動相を1分間保持、次いで、14分間かけて5〜99%のACN勾配で変化、次いで、99% ACNで10分間保持する、
又は
Gilson HPLCで、XBridge C18カラム(5μm、100×50mm)を使用し、80mL/分の流速で、10分間にわたり20mM NH4OH中5〜99%でACNの移動相を変化し、次に、99% ACNで2分間保持する、のいずれかで実施した。
MeOH中の冷却した(0℃)6−(トリフルオロメチル)ピリミジン−4−アミン(2.0g、12.3mmol)の溶液(100.0mL)に、臭素(1.3mL、24.5mmol)を10分を超えて滴下した。この混合物をrtで2時間撹拌した。反応物をH2Oでクエンチし、減圧下で濃縮して、粗HBr塩を得た(3.57g)。粗生成物をXBridge C18カラム(5μm、100×4.6mm)、20mMのNH4OH中10〜100% ACNの移動相を使用した逆相HPLCにより精製して、淡褐色固体として標題化合物を生成した(2.4g、80%)。MS(ESI):C5H3BrF3N3の質量計算値、241.9、m/z実測値、243.9[M+H]+。1H NMR(500MHz,DMSO−d6)δ 8.46(s,1H),8.25(s,1H),7.52(s,1H)。
DMF中の6−(トリフルオロメチル)ピリミジン−4−アミン(1.0g、6.2mmol)の溶液(30mL)に、NBS(1.2g、6.8mmol)を加えた。この混合物を70℃まで1時間加熱した。反応混合物をrtまで冷却し、H2Oで希釈し、EtOAcで抽出した(2回)。合わせた有機抽出物をブラインで洗浄し、乾燥させ(Na2SO4)、減圧下で濃縮した。粗生成物をDCMで粉末化して標題化合物を白色固体として得た(1.38g、93%)。
(0.32mL、1.79mmol)を注射器で滴下した。反応混合物をrtまで加温し、更に1時間撹拌した。反応物をEtOAcで希釈し、H2Oでゆっくりとクエンチした。水層をEtOAcで抽出し(2回)、合わせた有機物をブラインで洗浄し、乾燥させ(Na2SO4)、濾過した。濾液を減圧下で濃縮し、残渣を精製し(FCC、SiO2、0〜20% EtOAc/ヘキサン)、標題化合物を白色発泡体として得た(447mg、52%収率)。MS(ESI):C21H23ClF3N5OSiの質量計算値、481.1、m/z実測値、482.1[M+H]+。
方法A:マイクロ波バイアルに、7−クロロ−8−(7−メチル−1−((2−(トリメチルシリル)エトキシ)メチル)−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン(20mg、41.5μmol)、3−フルオロアゼチジン塩酸塩(6.9mg、62.2μmol)、RuPhos−Pd−G3プレ触媒(3.5mg、10mol%)、ナトリウムtert−ブトキシド(16.0mg、166μmol)、及び1,4−ジオキサン(0.67mL)を充填した。バイアルを排気し、N2で再充填(3回)した後、蓋をし、密封した。次いで、反応物をマイクロ波反応器で130℃で1時間撹拌した。次いで、混合物をEtOAc及びH2Oで希釈し、水層をEtOAcで抽出した(2回)。合わせた有機物をブラインで洗浄し、乾燥させ(Na2SO4)、濾過した。濾液を減圧下で濃縮し、残渣は更に精製せずに直接次の工程で使用した。MS(ESI):C24H28F4N6OSiの質量計算値、520.2、m/z実測値、521.1[M+H]+。
カルシウム流入アッセイ
このアッセイを用いて、TARPγ8依存性AMPA受容体活性を阻害できるかどうかについて化合物を試験した。AMPA受容体は、グルタミン酸塩によって活性化される非選択的カチオンチャネルである。イオンチャネル型グルタミン酸受容体は通常、脱感作が急速すぎて、FLIPRアッセイにおいて検出可能なカルシウム流入を可能にしない(Strange et al.(2006).「Functional characterisation of homomeric ionotropic glutamate receptors GluR1〜GluR6 in a fluorescence−based high throughput screening assay.」Comb Chem High Throughput Screen 9(2):147〜158)。しかし、この脱感作は不完全であり、実質的な定常状態の流れは、グルタミン酸の持続的存在下に留まる(Cho et al.(2007).「Two families of TARP isoforms that have distinct effects on the kinetic properties of AMPA receptors and synaptic currents.」Neuron 55(6):890〜904)。
内因性ガンマ8含有AMPA受容体電流に対する選択した化合物の効果を、急性的に分離したマウスの海馬ニューロンに対する全細胞電気生理学を用いて評価する。このアッセイのために海馬を選択したが、その理由は、CACNG8(この遺伝子によってコードされているタンパク質は、I型膜貫通AMPA受容体調節タンパク質、すなわち、TARPである)が、この脳領域に優先的に多く含まれているためである(Tomita et al.(2003).「Functional studies and distribution define a family of transmembrane AMPA receptor regulatory proteins.」J Cell Biol 161(4):805〜816.2003)。
Claims (26)
- 式(I):
Xは、N又はCHであり、
Yは、N、CH、CF、及びCClからなる群から選択され、
R1は、H又はCH3であり、
R2は、C1〜6アルキル、C1〜6ハロアルキル、CH2OCH3、C3〜8シクロアルキル及びフェニルからなる群から選択され、
R3は、H、ハロ、CH3及びCF3からなる群から選択され、
R4は、ハロ、C1〜6アルキル、C1〜6アルコキシ、C1〜6ハロアルキル、CN、C3〜8シクロアルキル、アゼチジニル、Fで置換されたアゼチジニル、及びFで置換されたフェニルからなる群から選択され、
その製薬上許容される塩、N−酸化物、又は溶媒和物。 - Xが、Nである、請求項1に記載の化合物。
- Xが、CHである、請求項1に記載の化合物。
- Yが、Nである、請求項1に記載の化合物。
- Yが、CH、CF、又はClである、請求項1に記載の化合物。
- Yが、CHである、請求項1に記載の化合物。
- R1が、Hである、請求項1に記載の化合物。
- R1が、CH3である、請求項1に記載の化合物。
- R2が、C1〜6アルキル、C1〜6ハロアルキル、CH2OCH3、シクロプロピル、シクロブチル、シクロペンチル、又はフェニルである、請求項1に記載の化合物。
- R2が、CH3、CH2CH3、CH(CH3)2、C(CH3)3、CF2H、CF3である、請求項1に記載の化合物。
- R2が、CF3である、請求項1に記載の化合物。
- R3が、H、F、I、又はCH3である、請求項1に記載の化合物。
- R4が、C1〜6アルキル、C1〜6ハロアルキル、Cl、CN、OCH3、Fで置換されたフェニル、シクロプロピル、シクロペンチル、アゼチジニル、Fで置換されたアゼチジニルである、請求項1に記載の化合物。
- R4が、CF3である、請求項1に記載の化合物。
- 以下からなる群から選択される化合物:
8−(7−クロロ−1H−インダゾール−5−イル)−2−(ジフルオロメチル)−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−クロロ−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
6−(2,7−ビス(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン−8−イル)ベンゾ[d]チアゾール−2(3H)−オン、
2−シクロブチル−7−(4−フルオロフェニル)−8−(7−メチル−1H−インダゾール−5−イル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
6−(7−(4−フルオロフェニル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン−8−イル)ベンゾ[d]チアゾール−2(3H)−オン、
7−シクロペンチル−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−(アゼチジン−1−イル)−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−(3−フルオロアゼチジン−1−イル)−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
2−シクロペンチル−7−(4−フルオロフェニル)−8−(7−メチル−1H−インダゾール−5−イル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン−7−カルボニトリル、
7−メチル−5−[7−メチル−2−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン−8−イル]インドリン−2−オン、
5−(7−(4−フルオロフェニル)−2−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン−8−イル)−1H−インダゾール、
8−(7−クロロ−1H−インダゾール−5−イル)−2,7−ビス(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−2−(ジフルオロメチル)−7−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
2−(ジフルオロメチル)−8−(7−メチル−1H−インダゾール−5−イル)−7−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
8−(7−メチル−1H−インダゾール−5−イル)−2−(ジフルオロメチル)−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−クロロ−5−(2−(ジフルオロメチル)−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン−8−イル)インドリン−2−オン、
7−メチル−5−(2−(ジフルオロメチル)−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン−8−イル)インドリン−2−オン、
8−(7−クロロ−1H−インダゾール−5−イル)−2,7−ビス(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
8−(7−メチル−1H−インダゾール−5−イル)−2,7−ビス(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
5−(2,7−ビス(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン−8−イル)−7−クロロインドリン−2−オン、
5−(2,7−ビス(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン−8−イル)−7−メチルインドリン−2−オン、
8−(7−クロロ−1H−インダゾール−5−イル)−7−(ジフルオロメチル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
8−(7−メチル−1H−インダゾール−5−イル)−7−(ジフルオロメチル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−クロロ−5−(7−(ジフルオロメチル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン−8−イル)インドリン−2−オン、
7−メチル−5−(7−(ジフルオロメチル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン−8−イル)インドリン−2−オン、
7−メチル−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−エチル−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−メトキシ−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
8−(7−クロロ−1H−インダゾール−5−イル)−2−シクロプロピル−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
2−シクロプロピル−8−(7−メチル−1H−インダゾール−5−イル)−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
8−(7−クロロ−1H−インダゾール−5−イル)−2−メチル−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
2−メチル−8−(7−メチル−1H−インダゾール−5−イル)−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
8−(7−クロロ−1H−インダゾール−5−イル)−2−エチル−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
2−エチル−8−(7−メチル−1H−インダゾール−5−イル)−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
5−[2−エチル−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン−8−イル]−7−メチル−インドリン−2−オン、
8−(7−クロロ−1H−インダゾール−5−イル)−2−イソプロピル−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
2−イソプロピル−8−(7−メチル−1H−インダゾール−5−イル)−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
5−[2−イソプロピル−7−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン−8−イル]−7−メチル−インドリン−2−オン、
2−イソプロピル−7メチル−8−(7−メチル−1H−インダゾール−5−イル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−クロロ−8−(7−クロロ−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−(4−フルオロフェニル)−8−(7−フルオロ−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−(4−フルオロフェニル)−8−(7−クロロ−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−(4−フルオロフェニル)−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
8−(3−フルオロ−1H−インダゾール−5−イル)−7−(4−フルオロフェニル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
2−(ジフルオロメチル)−7−(4−フルオロフェニル)−8−(7−メチル−1H−インダゾール−5−イル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−(4−フルオロフェニル)−2−(メトキシメチル)−8−(7−メチル−1H−インダゾール−5−イル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
2−シクロプロピル−7−(4−フルオロフェニル)−8−(7−メチル−1H−インダゾール−5−イル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
7−イソプロピル−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン、
8−(1H−インダゾール−5−イル)−7−メチル−2−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン、
7−フルオロ−5−[7−メチル−2−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン−8−イル]インドリン−2−オン、
7−メチル−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン、
2−tert−ブチル−7−メチル−8−(7−メチル−1H−インダゾール−5−イル)イミダゾ[1,2−a]ピリジン、
5−(2−tert−ブチル−7−メチル−イミダゾ[1,2−a]ピリジン−8−イル)7−メチル−インドリン−2−オン、
7−メチル−5−(7−メチル−2−フェニル−イミダゾ[1,2−a]ピリジン−8−イル)インドリン−2−オン、
7−メチル−8−(7−メチル−1H−インダゾール−5−イル)−2−フェニル−イミダゾ[1,2−a]ピリジン、
2−シクロプロピル−7−メチル−8−(7−メチル−1H−インダゾール−5−イル)イミダゾ[1,2−a]ピリジン、
5−[7−メトキシ−2−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン−8−イル]−7−メチル−インドリン−2−オン、
7−メトキシ−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン、
7−クロロ−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン、
5−(2,7−ビス(トリフルオロメチル)イミダゾ[1,2−a]ピリジン−8−イル)−1H−インダゾール、
5−(2,7−ビス(トリフルオロメチル)イミダゾ[1,2−a]ピリジン−8−イル)−7−メチル−1H−インダゾール、
8−(7−メチル−1H−インダゾール−5−イル)−2,7−ビス(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−2−エチル−7−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
2−エチル−8−(7−メチル−1H−インダゾール−5−イル)−7−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−2−イソプロピル−7−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−2−シクロプロピル−7−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
2−シクロプロピル−8−(7−メチル−1H−インダゾール−5−イル)−7−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
7−クロロ−5−[2−シクロプロピル−7−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン−8−イル]インドリン−2−オン、
5−[2−シクロプロピル−7−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン−8−イル]−7−フルオロ−インドリン−2−オン、
8−(7−クロロ−1H−インダゾール−5−イル)−7−イソプロピル−2−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−2−(ジフルオロメチル)−7−イソプロピル−イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−7−エチル−2−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
7−エチル−8−(7−メチル−1H−インダゾール−5−イル)−2−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−2−(ジフルオロメチル)−7−エチル−イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−7−メチル−2−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−7−シクロプロピル−2−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−7−シクロプロピル−2−(ジフルオロメチル)イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−7−シクロプロピル−5−メチル−2−トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−7−シクロプロピル−2−(ジフルオロメチル)−5−メチル−イミダゾ[1,2−c]ピリミジン、
3−クロロ−8−(7−クロロ−1H−インダゾール−5−イル)−2−シクロプロピル−7−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、及び
8−(7−クロロ−1H−インダゾール−5−イル)−2−シクロプロピル−3−フルオロ−7−(トリフルオロメチル)イミダゾ[1,2−c]ピリミジン、
5−(2,7−ビス(トリフルオロメチル)イミダゾ[1,2−a]ピリジン−8−イル)−7−クロロインドリン−2−オン、
5−(2,7−ビス(トリフルオロメチル)イミダゾ[1,2−a]ピリジン−8−イル)−7−メチルインドリン−2−オン、
5−(2,7−ビス(トリフルオロメチル)イミダゾ[1,2−a]ピリジン−8−イル)−7−クロロ−1H−インダゾール、
8−(7−クロロ−1H−インダゾール−5−イル)−2−イソプロピル−7−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン、
2−イソプロピル−8−(7−メチル−1H−インダゾール−5−イル)−7−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン、
2−シクロプロピル−8−(7−メチル−1H−インダゾール−5−イル)−7−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン、
2−エチル−8−(7−メチル−1H−インダゾール−5−イル)−7−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン、
2−(ジフルオロメチル)−8−(7−メチル−1H−インダゾール−5−イル)−7−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン、及び
2−メチル−8−(7−メチル−1H−インダゾール−5−イル)−7−(トリフルオロメチル)イミダゾ[1,2−a]ピリジン、並びに
その製薬上許容される塩、N−酸化物、又は溶媒和物。 - 以下からなる群から選択される化合物:
7−シクロプロピル−2−(ジフルオロメチル)−5−メチル−8−(7−(トリフルオロメチル)−1H−インダゾール−5−イル)イミダゾ[1,2−c]ピリミジン、
8−(7−クロロ−1H−インダゾール−5−イル)−7−(ジフルオロメチル)−2−エチル−[1,2,4]トリアゾロ[1,5−a]ピリジン、及び
8−(7−クロロ−1H−インダゾール−5−イル)−2−シクロプロピル−7−(ジフルオロメチル)−[1,2,4]トリアゾロ[1,5−a]ピリジン
並びにその製薬上許容される塩、N−酸化物、又は溶媒和物。 - (A)有効量の式(I):
Xは、N又はCHであり、
Yは、N、CH、CF、又はCClからなる群から選択され、
R1は、H又はCH3であり、
R2は、C1〜6アルキル、C1〜6ハロアルキル、CH2OCH3、C3〜8シクロアルキル及びフェニルからなる群から選択され、
R3は、H、ハロ、CH3及びCF3からなる群から選択され、
R4は、ハロ、C1〜6アルキル、C1〜6アルコキシ、C1〜6ハロアルキル、CN、C3〜8シクロアルキル、アゼチジニル、Fで置換されたアゼチジニル、及びFで置換されたフェニルからなる群から選択され、
式(I)の化合物の製薬上許容される塩、N−酸化物、又は溶媒和物、
の少なくとも1つと、
(B)少なくとも1つの製薬上許容される賦形剤と、
を含む医薬組成物。 - 有効量の請求項21に記載の少なくとも1つの化合物及び少なくとも1つの製薬上許容できる賦形剤を含む医薬組成物。
- AMPA受容体活性によって媒介される疾患、障害又は医学的状態に罹患しているか又はこれらの疾患、障害又は医学的状態であると診断された対象を治療する方法であって、このような治療を必要としている対象に、有効量の式(I):
Xは、N又はCHであり、
Yは、N、CH、CF、及びCClからなる群から選択され、
R1は、H又はCH3であり、
R2は、C1〜6アルキル、C1〜6ハロアルキル、CH2OCH3、C3〜8シクロアルキル及びフェニルからなる群から選択され、
R3は、H、ハロ、CH3及びCF3からなる群から選択され、
R4は、ハロ、C1〜6アルキル、C1〜6アルコキシ、C1〜6ハロアルキル、CN、C3〜8シクロアルキル、アゼチジニル、Fで置換されたアゼチジニル、及びFで置換されたフェニルからなる群から選択され、
式(I)の化合物の製薬上許容される塩、N−酸化物又は溶媒和物、
の少なくとも1つを投与することを含む、方法。 - 前記AMPA受容体によって媒介される疾患、障害又は医学的状態が、脳虚血、頭部外傷、脊髄損傷、アルツハイマー病、パーキンソン病、筋萎縮性側索硬化症(ALS)、ハンチントン舞踏病、AIDS神経障害、てんかん、精神障害、運動障害、疼痛、痙性、食品毒による神経障害、各種神経変性疾患、各種精神病、慢性疼痛、片頭痛、癌性疼痛、糖尿病性神経障害、脳炎、急性播種性脳脊髄炎、急性脱髄性多発神経障害(ギランバレー症候群)、慢性炎症性脱髄性多発神経炎、多発性硬化症、マルキアファーヴァビニャミ病、橋中心髄鞘崩壊症、デビック症候群、バロー病、HIV−又はHTLV−脊髄症、進行性多巣性白質脳症、二次性脱髄障害(例えば、CNSループスエリテマトーデス、結節性多発性動脈炎、シェーグレン症候群、サルコイドーシス、孤立性脳血管炎など)、統合失調症、前駆期統合失調症、認知障害、うつ病、不安障害、不安うつ病及び双極性障害から選択される、請求項24に記載の方法。
- 前記AMPA受容体によって媒介される疾患、障害又は状態が、うつ病、心的外傷後ストレス障害、てんかん、統合失調症、前駆期統合失調症又は認知障害である、請求項24に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662412867P | 2016-10-26 | 2016-10-26 | |
US62/412,867 | 2016-10-26 | ||
PCT/US2017/057564 WO2018080916A1 (en) | 2016-10-26 | 2017-10-20 | Fused azaheterocyclic compounds and their use as ampa receptor modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019532981A true JP2019532981A (ja) | 2019-11-14 |
JP6994029B2 JP6994029B2 (ja) | 2022-01-14 |
Family
ID=60263051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019522818A Active JP6994029B2 (ja) | 2016-10-26 | 2017-10-20 | 融合アザヘテロ環状化合物、及びampa受容体調節因子としてのそれらの使用 |
Country Status (12)
Country | Link |
---|---|
US (1) | US10155769B2 (ja) |
EP (1) | EP3532476B1 (ja) |
JP (1) | JP6994029B2 (ja) |
KR (1) | KR102417483B1 (ja) |
CN (1) | CN109890823B (ja) |
AU (1) | AU2017350688B2 (ja) |
CA (1) | CA3039208A1 (ja) |
CO (1) | CO2019004143A2 (ja) |
EA (1) | EA037731B1 (ja) |
IL (1) | IL266183B (ja) |
SG (1) | SG11201902882UA (ja) |
WO (1) | WO2018080916A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019536760A (ja) * | 2016-10-26 | 2019-12-19 | ヤンセン ファーマシューティカ エヌ.ベー. | 縮合二環ピリジン化合物、及びampa受容体調節因子としてのそれらの使用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4282416A3 (en) * | 2018-09-29 | 2024-03-06 | Novartis AG | Process of manufacture of a compound for inhibiting the activity of shp2 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008113795A1 (en) * | 2007-03-20 | 2008-09-25 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
JP2012510437A (ja) * | 2008-11-28 | 2012-05-10 | オルソー−マクニール−ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
WO2015183673A1 (en) * | 2014-05-28 | 2015-12-03 | Eli Lilly And Company | 6-substituted-3h-1,3-benzothiazol-2-one compounds as tarp-gamma 8 dependent ampa receptor antagonists |
WO2016176457A1 (en) * | 2015-04-29 | 2016-11-03 | Janssen Pharmaceutica Nv | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators |
JP2019536760A (ja) * | 2016-10-26 | 2019-12-19 | ヤンセン ファーマシューティカ エヌ.ベー. | 縮合二環ピリジン化合物、及びampa受容体調節因子としてのそれらの使用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1100504A2 (en) | 1998-07-02 | 2001-05-23 | Eisai Co., Ltd. | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
EP1797094A4 (en) * | 2004-08-03 | 2009-06-03 | Merck & Co Inc | 1,3-DISUBSTITUTED HETEROARYL-NMDA / NR2B ANTAGONISTS |
GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US8648085B2 (en) * | 2007-11-30 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders |
JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
TWI714567B (zh) * | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
-
2017
- 2017-10-20 AU AU2017350688A patent/AU2017350688B2/en active Active
- 2017-10-20 WO PCT/US2017/057564 patent/WO2018080916A1/en unknown
- 2017-10-20 KR KR1020197014641A patent/KR102417483B1/ko active IP Right Grant
- 2017-10-20 JP JP2019522818A patent/JP6994029B2/ja active Active
- 2017-10-20 EA EA201991045A patent/EA037731B1/ru unknown
- 2017-10-20 EP EP17794522.7A patent/EP3532476B1/en active Active
- 2017-10-20 CN CN201780066762.3A patent/CN109890823B/zh active Active
- 2017-10-20 CA CA3039208A patent/CA3039208A1/en active Pending
- 2017-10-20 SG SG11201902882UA patent/SG11201902882UA/en unknown
- 2017-10-23 US US15/790,809 patent/US10155769B2/en active Active
-
2019
- 2019-04-23 IL IL266183A patent/IL266183B/en unknown
- 2019-04-26 CO CONC2019/0004143A patent/CO2019004143A2/es unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008113795A1 (en) * | 2007-03-20 | 2008-09-25 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
JP2012510437A (ja) * | 2008-11-28 | 2012-05-10 | オルソー−マクニール−ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
WO2015183673A1 (en) * | 2014-05-28 | 2015-12-03 | Eli Lilly And Company | 6-substituted-3h-1,3-benzothiazol-2-one compounds as tarp-gamma 8 dependent ampa receptor antagonists |
WO2016176457A1 (en) * | 2015-04-29 | 2016-11-03 | Janssen Pharmaceutica Nv | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators |
JP2019536760A (ja) * | 2016-10-26 | 2019-12-19 | ヤンセン ファーマシューティカ エヌ.ベー. | 縮合二環ピリジン化合物、及びampa受容体調節因子としてのそれらの使用 |
Non-Patent Citations (2)
Title |
---|
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 10, no. 10, JPN6021048164, 2000, pages 1539 - 1548, ISSN: 0004656916 * |
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 23, no. 5, JPN6021048163, 2013, pages 615 - 628, ISSN: 0004656917 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019536760A (ja) * | 2016-10-26 | 2019-12-19 | ヤンセン ファーマシューティカ エヌ.ベー. | 縮合二環ピリジン化合物、及びampa受容体調節因子としてのそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
CN109890823B (zh) | 2021-11-30 |
KR102417483B1 (ko) | 2022-07-05 |
CN109890823A (zh) | 2019-06-14 |
AU2017350688A1 (en) | 2019-04-18 |
EP3532476A1 (en) | 2019-09-04 |
SG11201902882UA (en) | 2019-05-30 |
IL266183A (en) | 2019-06-30 |
US10155769B2 (en) | 2018-12-18 |
CA3039208A1 (en) | 2018-05-03 |
EA201991045A1 (ru) | 2019-09-30 |
CO2019004143A2 (es) | 2019-05-10 |
EP3532476B1 (en) | 2020-08-19 |
NZ751999A (en) | 2021-06-25 |
WO2018080916A1 (en) | 2018-05-03 |
IL266183B (en) | 2022-02-01 |
KR20190066068A (ko) | 2019-06-12 |
US20180111942A1 (en) | 2018-04-26 |
EA037731B1 (ru) | 2021-05-14 |
JP6994029B2 (ja) | 2022-01-14 |
AU2017350688B2 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7026194B2 (ja) | アザベンズイミダゾール及びamap受容体調節因子としてのその使用 | |
US10513523B2 (en) | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators | |
JP6953527B2 (ja) | 縮合二環ピリジン化合物、及びampa受容体調節因子としてのそれらの使用 | |
KR102417483B1 (ko) | 융합된 아자헤테로사이클릭 화합물 및 ampa 수용체 조절제로서의 이들의 용도 | |
JP6811187B2 (ja) | インドロン化合物、及びampa受容体調節因子としてのそれらの使用 | |
US10100045B2 (en) | 3-aryl-2H-pyrazolo[4,3-b]pyridine compounds and their use as AMPA receptor modulators | |
NZ751999B2 (en) | Fused azaheterocyclic compounds and their use as ampa receptor modulators | |
NZ751998B2 (en) | Fused bicylic pyridine compounds and their use as ampa receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201008 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210914 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211019 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6994029 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |